Determination of kanamycin plasma concentrations using LC/MS and pharmacokinetics of kanamycin in patients with multidrug-resistant tuberculosis and in patients with multidrug-resistant tuberculosis co-infected with HIV by Abaniwonda, Ibukunoluwa Mercy
I 
 
 
 
 
 
DETERMINATION OF KANAMYCIN PLASMA CONCENTRATIONS 
USING LC/MS AND PHARMACOKINETICS OF KANAMYCIN IN 
PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS AND IN 
PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS CO-
INFECTED WITH HIV 
 
 
Ibukunoluwa Mercy Abaniwonda  
 
A thesis submitted in fulfilment of the requirements for the degree of 
Magister Pharmaceuticiae in the School of Pharmacy, University of the 
Western Cape, Bellville, South Africa 
 
Supervisor: Prof. P. Mugabo 
 
November 2012. 
 
  
 
 
 
 
II 
 
Determination of kanamycin plasma concentrations using LC/MS and 
pharmacokinetics of kanamycin in patients with multidrug-resistant 
tuberculosis and in patients with multidrug-resistant tuberculosis co-infected 
with HIV 
 
Ibukunoluwa Mercy Abaniwonda 
 
Key words 
Multidrug-resistant tuberculosis 
HIV 
Liquid chromatography/ 
Mass spectrometry 
Pharmacokinetics 
Plasma concentrations 
Kanamycin 
  
 
 
 
 
III 
 
ABSTRACT  
 
DETERMINATION OF KANAMYCIN PLASMA CONCENTRATIONS 
USING LC/MS AND PHARMACOKINETICS OF KANAMYCIN IN 
PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS AND IN 
PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS CO-
INFECTED WITH HIV. 
 
I.M. Abaniwonda 
M.Pharm, School of Pharmacy, University of the Western Cape 
 
Pharmacokinetics (PK) of kanamycin has been studied in healthy volunteers using 
immuno assay methods. Little information exists on the PK of kanamycin in HIV-
negative patients infected with multidrug-resistant tuberculosis (MDR-TB), and 
currently there is no information on its PK in South African patients with MDR-
TB infection and in those with MDR-TB co-infected with HIV. Therefore, the aim 
of the study was to determine firstly, kanamycin plasma concentrations using 
liquid chromatography coupled with mass spectrometry (LC/MS); secondly, to 
investigate the PK parameters of kanamycin in patients infected with MDR-TB 
and in patients co-infected with MDR-TB and HIV; thirdly, to assess the 
influence of HIV infection and renal impairment on the PK of kanamycin and 
fourthly, to find out whether there is any interaction between antiretroviral drugs 
and kanamycin. 
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Blood samples were drawn at different times over 24 hours after kanamycin 
intramuscular administration. The plasma concentration-time profile for each 
patient was plotted manually and the non-compartmental analysis method was 
used to calculate PK parameters. 
 
The LC/MS analysis method was highly sensitive and specific in the detection and 
quantification of kanamycin in plasma. Separation of kanamycin peak was 
achieved at a retention time of 1.50 minutes with a high mean recovery percentage 
of 92.5%. 
 
Pharmacokinetic parameters were presented as median and range. The absorption 
rate (Ka), maximum plasma concentrations (Cmax), the time to the maximum 
plasma concentrations (Tmax), the area under the plasma concentration curve 
during 24 hours (AUC0-24), the area under the plasma concentration curve from 
zero to infinity (AUC0-∞), the elimination rate constant (Ke), the volume of 
distribution (Vd), the clearance (Cltot), the half-life (t1/2) and the mean residence 
time (MRT) in HIV -positive patients were 0.52 (0.16-0.90) hr
-1
, 18.19 (8.40-
27.63) µg/ml, 1.00 (0.50-2.00) hrs, 146.28 (60.22-305.86) µg/ml.hr, 190.33 
(71.32-453.32) µg/ml.hr, 0.18 (0.063-0.33) hr
-1
, 30.17 (13.28-87.63) L, 4.38 
(1.65-14.02) L/hr, 3.85 (2.10-11.00) hrs and 2.99 (1.11-12.96) hrs, respectively; 
and in HIV -negative patients, 18.39 (13.32–25.26) µg/ml, 1.00 (0.50-2.00) hours, 
161.90 (54.36–192.68) µg/ml.hr, 236.60 (60.06-295.63) µg/ml.hr, 0.13 (0.081-
0.35) hr
-1
, 33.02 (14.89–45.59) L, 4.00 (3.01–15.04) L/hr, 5.37 (1.98–8.56) hours, 
and 4.44 (1.13–12.76) hours, respectively.  
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There was no statistical significant difference in the PK parameters in the HIV-
positive and HIV-negative patients, with the smallest p value being 0.43. A 
statistical significant difference (p=0.013) was found in the renal function in HIV 
-positive and HIV -negative patients. However, the difference did not result into 
affecting the PK parameters of kanamycin (p=0.31).  
 
We had an unequal distribution of patients in the HIV -positive and HIV -negative 
groups with regards to CD4 counts and viral load, imbalance in the different 
categories of renal dysfunction and stages of HIV disease. Therefore, we 
recommend further studies with a higher sample size of patients to address the 
unequal distribution with regards to the immunological and virological profile, 
categories of renal dysfunction and stages of HIV disease. 
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CHAPTER 1: INTRODUCTION AND RATIONALE OF THE STUDY 
 
1.1 Tuberculosis and human immunodeficiency viral infection: Globally and 
in South Africa  
The scale of the tuberculosis (TB) pandemic is growing worldwide. The 
bacterium Mycobacterium tuberculosis (MTB) is responsible for this infection 
and is the most common cause of death among patients infected with human 
immunodeficiency virus (HIV). The World Health Organisation (WHO) reports 
that one-third of the world’s population is currently infected with tuberculosis 
(WHO, 2008). The number of TB and HIV infections is raising concerns globally, 
and particularly in sub-Saharan Africa. In South Africa, 400,000 new cases of TB 
are reported each year (WHO, 2011), while sub-Saharan Africa has the greatest 
burden of TB and HIV in the world. In this region, the surge of HIV has been an 
important factor in the development of active TB, making it difficult for TB 
control programmes to be successful. 
 
Despite the introduction of control programmes, the number of TB cases in sub-
Saharan Africa has risen dramatically. In a study by WHO in 2009, it was 
estimated that the national directly observed treatment (DOT) success rate in 
South Africa was recorded to have increased from 65% in 2001 to 74% in 2006. 
Therefore, the increase of TB in sub-Saharan Africa is not due to the failure of 
control programmes, but principally due to the link between TB and HIV, because 
each disease accelerates the progress of the other. It has been estimated that 70% 
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of new adult patients with TB annually are co-infected with HIV in South Africa 
(WHO, 2009). 
 
Furthermore, improper treatment of TB can lead to the development of multidrug-
resistant tuberculosis (MDR-TB), which is TB that is resistant to at least isoniazid 
(INH) and rifampicin (RIF), the most potent anti-TB first-line drugs. The rise of 
MDR-TB in sub-Saharan Africa is causing concern and is complicated by HIV 
infection, thus making elimination of the drug-resistant bacteria difficult. It has 
been reported that approximately 5% of new cases of TB are MDR-TB globally 
(Mitnick et al., 2008; Farley et al., 2011). In addition, compared with drug-
resistant tuberculosis, MDR-TB therapy is complicated and involves the use of 
second-line anti-TB drugs that are more expensive and less potent, but with more 
side effects, and treatment is for a minimum of 18–24 months. 
 
Another factor threatening the control of TB is the presence of extensively drug-
resistant tuberculosis (XDR-TB). Studies done in KwaZulu-Natal Province in 
South Africa reported that the prevalence of XDR-TB was found to be 6% among 
patients with TB and that mortality rates were extremely high (98%) in HIV-
infected individuals with XDR-TB (Gandhi et al., 2006). This suggests that the 
development of resistance to at least INH and RIF, and to at least one of the three 
injectable second-line anti-TB drugs is not likely to be controlled, due to HIV 
infection. 
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1.2 Rationale of the study 
HIV infection has been noted to change the pharmacokinetics (PK) of first-line 
anti-TB drugs in HIV-positive patients co-infected with TB. It has been suggested 
that approximately 5% of HIV-positive patients on anti-TB treatment do not 
respond to the standard regimen of TB treatment, as compared to 0.4% of HIV-
negative patients (Aaron et al., 2004).  
 
In addition, many studies have confirmed that HIV -positive patients do not 
sufficiently absorb anti-TB drugs, resulting in sub-therapeutic outcomes of anti-
TB therapy that may result in the development of resistance to anti-TB drugs 
(Choudri et al. 1997; Peloquin, 2002; Gurumurthy et al., 2004). This evidence has 
not yet been confirmed for many of the second-line anti-TB drugs. 
 
Furthermore, the cure rate of MDR-TB infection in HIV-infected individuals is 
found to be lower due to high mortality rates than in HIV-negative patients. 
Studies have shown that the median sputum culture conversion rate from positive 
to negative was similar in both HIV-positive and HIV-negative groups of patients 
(Brust et al., 2011; Issakidis et al., 2011). However, individual competing factors 
(treatment default or death) suffered by HIV-positive patients altered the sputum 
conversion rate (Issakidis et al., 2011). Sputum culture conversion has been 
reported to indicate treatment outcomes, and MDR-TB patients with no sputum 
conversion within two to three months had high rates of relapse and failure (Brust 
et al., 2011). However, the inclusion of anti-retroviral therapy (ARV) with MDR-
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TB therapy might improve survival and treatment outcomes for MDR-TB patients 
co-infected with HIV.  
 
Many of the patients infected with MDR-TB and co-infected with HIV are on 
ARV therapy, therefore the interaction between ARVs and anti-TB drugs needs to 
be looked into. Interactions between ARV drugs and anti-TB drugs alter the 
plasma drug concentrations of anti-TB drugs by changing the absorption, 
distribution, hepatic metabolism and renal elimination of anti-TB drugs. For first-
line anti-TB drugs, major drug-to-drug interaction occurs between RIF and highly 
active antiretroviral therapy, protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors (Burman et al., 1999; Aaron et al., 2004; CDC, 2007). For 
second-line anti-TB drugs, interaction between tenofovir and kanamycin as a 
result of reduced elimination by the kidneys could result in an increase in the 
plasma concentration of kanamycin.  
 
Furthermore, it is known that currently used first- and second-line anti-TB drugs 
are different in their mechanism of action and these variations are mainly 
determined by their pharmacodynamic (PD) properties, that is their intrinsic 
activity profile, as well as their PK properties, such as absorption, disposition and 
tissue distribution profile (Budha et al., 2008). Consequently, a better 
understanding of the PK and PD of anti-TB drugs should improve treatment of 
mycobacterial infections and a more rational use of anti-TB therapy both in 
patients with MDR-TB infection and in patients co-infected with MDR-TB and 
HIV. In this study, only the PK of kanamycin in patients with MDR-TB and in 
 
 
 
 
5 
 
patients with MDR-TB co-infected with HIV will be determined due to budget 
and time constraints. Kanamycin is one of the drugs used in the intensive phase 
treatment of MDR-TB. Consideration of its PK in developing a dosage regimen 
could lead to better treatment outcomes in patients with MDR-TB and in patients 
with MDR-TB co-infected with HIV, as a poor dosage regimen could lead to 
treatment failure.  
 
The PK of kanamycin has been studied in healthy volunteers using 
microbiological assay methods and to a limited extent in patients with MDR-TB 
(Kirby et al., 1976; Pechere and Dugal., 1979; Holdiness, 1984; Douglas and 
Mcleod, 1999; Nuermberger and Grosset, 2004; Budha, 2008; Coyne et al., 2009). 
To the best of my knowledge, there is no recent published study on the analysis of 
kanamycin plasma concentrations using liquid chromatography (LC) coupled with 
mass spectrometry (MS). In addition, little information exists on the PK of 
kanamycin in HIV -negative patients infected with MDR-TB (Yew et al., 1999), 
and currently there is no information on its PK in South African patients with 
MDR-TB infection and in patients with MDR-TB co-infected with HIV (Mugabo, 
2009). Furthermore, information obtained from this study might help the future 
development of therapeutic drug monitoring in order to improve patients’ 
outcome and optimise drug therapy.  
 
Hence, the aim of the study was to determine kanamycin plasma concentrations 
using LC/MS and to describe the PK of kanamycin in patients with MDR-TB and 
in patients with MDR-TB co-infected with HIV during their course of treatment. 
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This was done by collecting blood samples from patients at different time 
intervals in a heparinised tube after patients attained the steady state concentration 
and then running various tests. The influence of HIV, kidney dysfunction and 
drug interactions on the PK of kanamycin were also determined. 
 
For the determination and quantification of kanamycin plasma concentration, 
LC/MS was utilised because of its high sensitivity and specificity as compared to 
other methods used in previous studies (Stead, 2000; La and Feng, 2007). 
 
1.3 Structure of the thesis 
Chapter one presents an overview of TB and HIV globally and in South Africa. It 
also provides the rationale of the study and the method to be used in determining 
kanamycin plasma concentration.  
 
The rest of the thesis is structured as follows: the literature is extensively 
reviewed in the following chapter. In the literature review, the pathogenesis of 
TB, the causes of anti-TB drug resistance, the development of MDR-TB and the 
influence of both TB and HIV on each other are presented. The effects of drug 
interaction and diseases on the PK of kanamycin are explained. The chapter also 
gives an overview of the risk factors for kidney and liver impairment. 
Furthermore, a review of the PK of kanamycin in healthy volunteers and in 
patients with MDR-TB is presented. Previous methods used in the analysis of 
kanamycin are also reviewed.  
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In the third chapter, a comprehensive description of methods used in the study is 
provided. In addition, the method used for the calculation of kanamycin PK 
parameters and statistical methods are explained.  
 
The fourth chapter presents the results obtained in the study. Here, the 
demographic data, immunological and virological profile, and biological profile 
of the patients are provided. In addition, the plasma concentrations and the PK 
parameters of kanamycin are presented. 
 
The fifth chapter discusses the results obtained. The first section explains the 
statistical analysis of the PK parameters of kanamycin. The demographic data, 
study procedures, the LC/MS method of analysis and laboratory results are 
discussed according to standardised conditions. Research questions that were 
drawn from the literature review are then answered. The clinical and therapeutic 
implications of the results are also highlighted in this chapter. Finally, the 
limitations of the study are explained. 
 
In the sixth chapter, the main findings of the study are summarised. In addition, 
recommendations and justification for further studies are included.   
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Structure of the literature review 
Chapter 2 provides a review of the literature on a number of aspects relating to the 
study. It consists of ten sections.  
 
The first section provides the structure of the literature review. 
 
The second section presents an overview of TB and gives a brief explanation of 
the pathogenesis of MTB, the development of active tuberculosis and the 
influence of active TB on the course of HIV infection, and vice versa. 
 
The third section gives a brief definition of drug-resistant tuberculosis, the 
epidemiology of MDR-TB, the mechanism of drug resistance, the causes of drug 
resistance, the laboratory identification of MDR-TB strains, the diagnosis of 
MDR-TB and the chemotherapy of MDR-TB. 
 
The fourth section gives an overview of the definition and purpose of PK studies, 
PK drug interactions, the influence of co-existing diseases on the PK of 
kanamycin, and drugs with side effects that may affect the PK of anti-TB drugs. 
 
The fifth section discusses drug interactions between ARVs and anti-TB drugs, 
with emphasis on the interaction between tenofovir and kanamycin. The sixth 
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section gives an overview of kidney and liver function tests and the risk factors 
for kidney and liver impairment. 
 
The seventh section describes the PK and pharmacology of kanamycin. It also 
presents published findings on the PK of kanamycin in healthy volunteers and in 
MDR-TB patients, clinical uses, drug interactions, side effects and the PK–PD 
relationship. This section also discusses how therapeutic drug monitoring (TDM) 
may help to optimise kanamycin dose. 
 
The eighth section presents a description of the methods used for the 
determination of the plasma concentration of anti-TB drugs, a description of the 
LC/MS method of analysis and previously used methods for the analysis of 
kanamycin. Lastly, it gives a review of published methods previously used to 
determine kanamycin plasma concentrations.  
 
The ninth section outlines the hypothesis of the thesis, while the tenth section 
presents the research questions and objectives of the study. 
 
2.2 Overview of tuberculosis 
2.2.1 Pathogenesis of Mycobacterium tuberculosis infection 
Understanding the process in the development of TB is important so as to 
understand the risk TB infection poses if it is not treated effectively. MTB is 
acquired by the inhalation of infectious airborne particles small enough (1–5 
microns) to reach alveolar air spaces (Shafer and Edlin, 1996). The possibility of 
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MTB infection depends on the intensity of MTB exposure and probably also on 
the effectiveness of innate host defences.  
 
Alveolar macrophages act as phagocytes of the innate immune system. Alveolar 
macrophages in some individuals might have a degree of innate mycobacterial 
resistance and in some other individuals the bacilli are presumably destroyed 
before infection is established. Furthermore, active TB disease following infection 
with MTB is not developed in some individuals because cell-mediated immunity 
is developed within two to ten weeks after initial infection (Weyer, 1999).  
 
2.2.2 Development of active tuberculosis 
The immunologic response to MTB infection does not always eliminate 
susceptible bacteria, since dormant organisms often reactivate latent infection. It 
was reported that in immuno-competent individuals, 20–50% may become 
infected after exposure for a prolonged period (hours/days rather than minutes) to 
MTB infection. In 90% of infected individuals MTB may become latent, while a 
few (5%) may develop TB early (typically within two years of infection) and an 
additional few (5%) may develop TB afterwards due to an impaired immune 
system (Weyer, 1999). 
 
2.2.3 Human immunodeficiency viral infection and reactivation of latent 
mycobacterium tuberculosis infection 
The risk of reactivating dormant MTB infection is greatly increased in HIV-
infected individuals as a result of HIV. It is known that CD4+ T-lymphocytes are 
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involved in the processes of the immune response to MTB, including binding to 
processed antigen, secreting cytokines and killing mycobacteria-infected cells 
(Shafer and Edlin, 1996).  
 
HIV increases the risk of advanced TB disease by inducing CD4+ T-lymphocyte 
depletion, leading to an ineffective immunologic response to MTB infection. It 
has been suggested that HIV co-infection with dormant TB results in a 50 times 
greater risk of the victim acquiring active TB disease and becoming infectious in 
the HIV population as compared to the non-HIV population (Bauer et al., 2008). 
Furthermore, the development of active TB following the activation of MTB 
infection in HIV-infected individuals occurs at higher CD4 counts (300–400 
cells/mm
3
) than other HIV-related illnesses. This is because HIV-infected 
individuals are more prone to developing active TB when newly infected or 
reinfected with MTB. 
      
2.2.4 Impact of active tuberculosis on the course of human immunodeficiency 
viral  infection 
Active TB also plays a role on the course of HIV infection by depleting the 
number of CD4+ T-lymphocytes, which increases HIV replication (Taylor, 1997; 
Perrone, 1999). TB also induces immune stimulation via the increased production 
of cytokines, such as tumour necrosis factor cellularly, which could be deleterious 
in HIV-infected individuals (Wallis et al., 1993; Shafer and Edlin, 1996). 
Furthermore, opportunistic infections and death are considered to be a greater 
threat in HIV-infected individuals co-infected with TB than in HIV-infected 
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patients with similar CD4+ cell counts without active TB (Shafer and Edlin, 
1996). This is due to the impaired immune system in HIV-infected individuals as 
a result of active TB. 
 
A study was done by Whalen et al. (1995) to compare the incidence of 
opportunistic infection in HIV-infected persons with active TB (comprising the 
cases) and in HIV-infected persons without active TB (comprising the control). 
The CD4+ counts were similar for both groups of patients and the result showed 
that the incidence rate of new cases of AIDS-defining opportunistic infections in 
patients with HIV and active TB were higher than in control subjects. It was 
recorded that there were 4.0 infections per 100 persons for the cases, compared to 
2.8 infections per 100 persons for control subjects. In addition, cases had shorter 
overall survival times as a result of active TB than control subjects. Therefore, it 
is probable that the increased burden of HIV co-infection with TB increases 
susceptibility to MTB infection, as well as increasing the risk of relapse of TB and 
the development of MDR-TB (Aaron et al., 2004). 
 
2.3 Drug-resistant tuberculosis 
2.3.1 Epidemiology of multidrug-resistant tuberculosis 
The rise of MDR-TB cases in the world poses a risk to TB control, and once again 
sub-Saharan Africa is considered to have the worst epidemic. An estimated 
489,139 new cases, or approximately 5% of new TB cases diagnosed in the world 
in 2006, were believed to be MDR-TB (Mitnick et al., 2008), and in South Africa 
there should be at least 2,000 newly active cases of MDR-TB each year (Budha et 
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al., 2008). According to the WHO global report on TB, the number of MDR-TB 
cases in South Africa has more than tripled, from 2,000 cases in 2005 to 7,350 in 
2007 (WHO, 2009). 
 
2.3.2 Mechanisms of tuberculosis drug resistance 
Mutations in genes encoding the targets of anti-TB therapy are primarily 
responsible for the resistance of MTB to anti-TB drugs (Shafer and Edlin, 1996). 
These mutations lead to an altered target of anti-TB agents, for example, RNA 
polymerase and catalase-peroxidase in RIF and INH resistance, respectively 
(Rattan et al., 1998). These alterations occur with a predictable frequency of one 
in 10
5–108 organisms (Shafer and Edlin, 1996).  
 
Drug resistance is categorised into primary, acquired or initial types based on 
patients’ history of prior TB treatment. Primary resistance to anti-TB drugs occurs 
in patients with no history of previous TB treatment. According to WHO, drug 
resistance among new cases is characterised by the presence of resistant strains of 
MTB in patients who have never received TB drugs or who have received TB 
drugs for less than one month of treatment (Chaulet and Maher, 1997).  
 
Acquired resistance refers to resistance to anti-TB drugs in patients with previous 
TB treatment. By definition, acquired resistance can only be established in 
patients who have received at least four weeks of anti-TB chemotherapy 
(Loddenkamper et al. 2002).  
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Initial resistance refers to drug resistance in patients with new cases of TB, as well 
as those with undisclosed acquired resistance (Loddenkamper et al., 2002). 
According to WHO, in cases where previous TB treatment in patients is unknown, 
this form of resistance is called initial resistance (Chaulet and Maher, 1997). 
 
2.3.3 Causes of drug resistance 
The development of resistance to anti-TB treatment is often thought to be 
commonly caused by non-adherence to anti-TB treatment; however, studies have 
shown that the organisational failure of TB control programmes, the lack of 
available drugs and clinical errors are responsible for many of the MDR-TB 
problems existing today (Loddenkamper et al., 2002; Wells et al., 2007). Common 
clinical errors include inadequate primary regimen, failure to provide DOT and 
failure to recognise existing drug resistance.  
 
Furthermore, based on epidemiology studies, the relationship between HIV 
infection and MDR-TB has not been established in sub-Saharan Africa 
(Wilkinson et al., 1996; Kenyon et al., 1999; Churchyard et al., 2000; WHO, 
2004). Notwithstanding, clinical evidence has shown that there is a link between 
HIV infection and the development of resistance to anti-TB drugs (Patel et al., 
1995; Choudri et al., 1997; Peloquin, 2002; Gurumurthy et al., 2004; Tappero et 
al., 2005).  
 
It has been reported that HIV-positive patients being treated in hospitals for drug-
susceptible TB have been infected with MDR-TB (Wells et al., 2007). In South 
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Africa, high HIV prevalence and the lack of ventilation measures in hospital 
wards have contributed to the spread of drug-resistant organisms among HIV-
positive individuals (Andrews et al., 2007). Hence, the sub-optimal control of TB 
infection and the increasing epidemic of HIV lead to the development of MDR-
TB.  
 
2.3.4 Laboratory identification of multidrug-resistant tuberculosis strains 
Laboratory identification of MDR-TB strains can only be established through 
culture and drug-susceptibility testing of the organism (Chaulet and Maher, 1997). 
Proportion method is commonly used for determining the drug susceptibility of 
MTB isolates in the laboratory. When 1% or more of the bacterial population 
becomes resistant to the critical concentration, MTB isolate is regarded as 
resistant to that drug (Chaulet and Maher, 1997). 
 
2.3.5 Diagnosis of multidrug-resistant tuberculosis 
MDR-TB is suspected in patients with persistent acid-fast bacilli smears or 
cultures, despite well-documented TB treatment adherence (Weyer, 2005). MDR-
TB can only be diagnosed by in-vitro confirmation of resistance. Inadequate 
clinical response to TB treatment is usually characterised in patients by acid-fast 
bacilli smears being positive at two months, which necessitates doing culture and 
susceptibility tests against INH and RIF (Loddenkamper et al., 2002; Weyer, 
2005). 
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2.3.6 Chemotherapy of multidrug-resistant tuberculosis 
The treatment for tuberculosis involves the use of first-line drugs, namely, INH, 
RIF, ethambutol and pyrazinamide, for a minimum of six to nine months (Chaulet 
and Maher, 1997; Budha et al., 2008). These drugs are used in the standardised 
treatment regimen, with an initial, intensive phase of two months and a 
continuation phase for four to six months (WHO, 2008). This anti-TB regimen 
does not always achieve elimination of MTB, as confirmed by treatment failure in 
some treated individuals. 
 
MDR-TB therapy is usually more expensive than first-line anti-TB drugs. This is 
because treatment of MDR-TB is for a minimum of 18–24 months rather than a 
minimum of 6–12 months for drug-sensitive TB. Furthermore, second-line anti-
TB drugs are more toxic than first-line drugs (Davies, 2001; Loddenkemper et al., 
2002; Budha et al., 2008). The second-line drugs that are available for the 
treatment of MDR-TB infection, in order of decreasing activity, include an 
aminoglycoside (amikacin or kanamycin), a thioamide (ethioamide or 
prothioamide), pyrazinamide, a fluoroquinolone (ciprofloxacin or ofloxacin), 
ethambutol, terizidone or cycloserine and para-aminosalicyclic acid (Weyer, 
2005).  
 
In developed countries, treatment of MDR-TB is based on drug susceptibility 
tests. This means that MDR-TB treatment is delayed until susceptibility tests are 
available or patients are started on standardised regimen while awaiting drug 
susceptibility tests. However, in resource-poor countries, the WHO treatment 
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guidelines are used in addition to DOT-based regimens. In South Africa, the 
regimen consists of a six-months daily intensive phase with five drugs: 
kanamycin, pyrazinamide, ofloxacin, ethionamide and either terizidone or 
ethambutol, followed by a continuation phase of 12–24 months with three drugs: 
ofloxacin, ethionamide and either ethambutol or terizidone (Weyer, 2005).  
 
The drugs used in the intensive and continuous phases and the dosages of these 
drugs are given in Tables 2.1 and 2.2.  
 
Table 2.1: Second-line anti-TB drugs used in the intensive phase (6 months) 
in South Africa 
MDR-TB drug Daily dosage (mg) 
Kanamycin 750–1,000 
Ethionamide 500–750 
Pyrazinamide 1,000–1,500 
Ofloxacin 600–800 
Ethambutol 800–1,200 
 
Table 2.2: Second line anti-TB drugs used in the continuation phase (12–24 
months) in South Africa 
MDR-TB Drug Daily dosage (mg) 
Ethionamide 500–750 
Ofloxacin 600–800 
Terizidone 750 
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Ethambutol (800–1,200mg) is used if the MDR-TB strain is sensitive to 
ethambutol. 
 
2.4 Pharmacokinetics 
2.4.1 Overview 
The term ‘pharmacokinetics’ describes the kinetics of drug absorption and 
disposition. Drug disposition involves processes of distribution and elimination 
(metabolism and excretion) (Budha et al., 2008).  
 
The purpose of PK studies in healthy volunteers or patients is usually to ascertain 
the association among the dose, dosage form and plasma concentration, and to 
gain knowledge on drug absorption and disposition (Derendorf et al., 2000). PK 
studies rely on the measurement of active drug ingredient in a biological fluid 
such as blood, plasma or urine. From these assays, concentration-time curves may 
be constructed and PK measures and parameters such as area under the 
concentration-time curve (AUC), maximum concentration (Cmax), clearance (Cl), 
volume of distribution (Vd) and half-life (t1/2) may be calculated (Derendorf et al., 
2000). 
 
2.4.2 Pharmacokinetic parameters 
Understanding PK parameters is important in determining the time course of an 
antimicrobial effect and in determining the optimum dose of an antibiotic. The 
important PK parameters used in the study are as follows: 
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 Cmax is the maximum concentration a drug achieves in blood plasma.  
 Tmax is the time taken to reach Cmax after drug administration.  
 T1/2 is the plasma half-life. It is the time taken for the drug plasma concentration 
levels to fall by 50%. 
 AUC is the area under the plasma concentration-time curve. It is the overall 
amount of drug in the blood stream after a dose. 
 Ke is the drug’s elimination rate constant. 
 Ka is the drug’s absorption rate constant. 
 Cl is the drug clearance, that is, the measure of the ability to eliminate a drug. The 
total body systemic clearance (Cltot) of a drug is the sum of the clearances of the 
drug by various organs and tissues of the body. 
 Vd is the apparent volume of distribution of the drug. It is the measure of the 
available apparent space in the body that is available to contain the drug. 
 MRT is the mean residence time of the drug. It is the average time that the drug 
molecules spend in the body. 
 
2.4.3 Pharmacokinetics of commonly used anti-retroviral drugs 
2.4.3.1 Stavudine 
The bioavailability of stavudine in the adult population infected with HIV is 82–
99% (Lea and Diana, 1996). Food considerably lowers the rate of absorption. The 
Cmax of stavudine is concentration dependent and Tmax is reached within 0.5–0.75 
hours after oral administration. The steady state volume of distribution is 47.3–
68.9 L in adults and the t1/2 of stavudine-5-triphosphate is 3.5 hours (Lea and 
Diana, 1996). 
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2.4.3.2 Lamivudine 
After oral administration, lamivudine is rapidly absorbed, with Cmax usually 
attained 0.5–1.5 hours after the dose (Johnson et al., 1999). Absolute 
bioavailability was recorded as 82% and 68% in adults and children, respectively. 
Food intake does not lower the rate of absorption of lamivudine. The elimination 
t1/2 of lamivudine is approximately 5–7 hours (Johnson et al., 1999). 
 
2.4.3.3 Efavirenz 
Oral clearance was recorded as 9.4 L/hr, oral volume of distribution was 252 L 
and absorption rate constant was 0.3 hr
-1 
(Almond et al., 2005). 
 
2.4.4 Pharmacokinetic drug interactions 
The administration of two or more drugs at the same time to the same patient can 
alter the absorption, distribution, hepatic metabolism and renal elimination of the 
drugs involved. 
 
2.4.4.1 Drug interaction during absorption 
Drug absorption is the movement of drug molecules from the site of 
administration into systemic circulation (Peloquin, 2002). Interactions between 
two drugs or between food or drinks and drugs can happen when they interfere 
with each other’s absorption. The absorption rate of a drug may be increased or 
decreased by the pH of the medium around the site of absorption and the acid 
dissociation constant (pka) of the drug. For example, the absorption rate of weak 
acidic drugs will be higher in the stomach where the pH is acidic, as opposed to 
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the alkaline pH in the small intestine. The absorption rate of a weak basic drug 
will be increased in the small intestine, where the pH is alkaline.  
 
Food can affect the rate of absorption of a drug taken concurrently, thereby 
affecting the bioavailability of the drug. Grapefruit has been found to interfere 
with drugs that undergo CP450 oxidative metabolism in the intestinal wall or 
liver. It interferes with these drugs by binding to the iso-enzyme, CYP3A4 as a 
substrate and impairs first-pass metabolism through the inhibition of CYP3A4; the 
result is an increase in the bioavailability of these drugs and an increased risk of 
serious side effects (Leucuta and Nlase, 2006). 
 
The poor absorption of anti-TB drugs results in sub-therapeutic plasma 
concentration levels and treatment failure of such drugs, with increased risk of 
acquired drug resistance (Gurumurthy et al., 2004). Therefore, an understanding 
of the PK parameters of anti-TB drugs will be effective in the rational treatment of 
patients infected with TB and in the prevention of drug resistance to anti-TB 
therapy. 
 
2.4.4.2 Hepatic drug metabolism 
Drug metabolism mediated by the CP450 system mainly occurs in the liver. 
Therefore, any dysfunction of the liver may lead to changes in drug metabolism. 
Drugs metabolised by the CP450 system can be classified as cytochrome P450 
substrates, inhibitors or inducers. Efavirenz, an ARV, is metabolized by CYP450. 
It is a 3A4 inducer and inhibitor and therefore interacts with other drugs 
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administered concomitantly (Almond et al., 2005). Inhibition of CP450 is usually 
reversible and competitive, such that the substrate and inhibitor compete for the 
same site on the enzyme. Drugs that inhibit CP450 can cause reduced clearance 
and increased plasma concentration of drugs metabolised through the CP450 
enzyme system. Similarly, drugs that induce the CP450 system increase the rate of 
liver metabolism. Induction of the CP450 pathway then leads to increased 
clearance and a subsequent fall in the plasma concentration of drugs metabolised 
by the pathway (Tang et al., 2005). 
 
2.4.4.3 Drug interaction during distribution 
The ability of a drug to produce the required pharmacological effect may be 
influenced by the extent to which the drug binds to proteins within the blood 
plasma. Drug–protein binding is reversible and equilibrium is established between 
the bound and unbound drug, regardless of the extent of protein binding. The less 
bound a drug is, the more effective it is, since it can cross cell membranes. 
Normally, it is the unbound fraction of a drug that exhibits pharmacological 
effects.  
 
If both drug A and drug B are highly protein bound (>90) and are given at the 
same time, they will both compete for protein-binding sites. If drug A is more 
competitive, it might displace drug B from the binding sites, increasing drug B’s 
unbound fraction. This may increase the effects of drug B. This change in 
pharmacological effect could have adverse effects in the patient. 
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2.4.4.4 Renal elimination 
Drug–drug interactions at the renal level can involve several mechanisms. For 
example, reduced plasma binding (competitive or non-competitive binding 
displacement) leads to an increase in the excretion of highly bound drugs through 
an increase in glomerular filtration (Bonate et al., 1998).  
 
In addition, the pH of urine and pka of the drug can influence the extent of the 
passive reabsorption of the drug. This mechanism is clinically significant for 
drugs that are excreted unchanged and have a narrow therapeutic index, such that 
changes in urine pH can interfere with plasma concentration. For example, the 
acidification of urine pH can increase the rate of passive reabsorption of weak 
acidic drugs, resulting in an increase in the half-life of the drug and therefore 
increased risk of drug interaction. Similarly, the alkalinisation of the urine pH can 
increase the rate of passive reabsorption of weak basic drugs, resulting in the 
increased plasma concentrations of the drug and consequently increased risk of 
drug interactions.  
 
The most notable mechanism of renal drug interaction is alteration of tubular 
active transport. Many drug transporters are actively responsible for the secretion 
and reabsorption of drugs in the kidney (Keith, 2006). Transporters are specific 
and are susceptible to competitive drug–drug interactions.  
 
Competition between two drugs for the same transporter protein inhibits the renal 
clearance of one of the drugs and this result in the increased plasma concentration 
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of the other drug that is a substrate of the transporter. In several cases, this 
increased plasma concentration can lead to increased toxic levels of the drug. For 
example, the inhibition of transporter organic anion transporting polypeptide by 
trimethoprim decreases lamivudine excretion into the proximal tubule, resulting in 
the increased plasma exposure of lamivudine (Taft, 2009). 
 
2.4.5 Influence of diseases on the pharmacokinetics of anti-tuberculosis drugs 
Drugs are developed to treat diseases, but sometimes these disease conditions can 
impair the PK of these drugs and affect patient response to drug therapy. 
Conditions affecting the gastro-intestinal tract, liver, heart and kidneys may 
increase or decrease the PK of drugs used for the treatment of MDR-TB by 
altering their absorption, distribution, metabolism and elimination. Some of these 
conditions are gastro-enteritis, diarrhoea, malabsorption syndromes, hepatitis, 
cirrhosis of the liver, congestive cardiac failure, renal failure and HIV infection. 
 
2.4.5.1 Gastro-enteritis 
Gastro-enteritis is the inflammation of the stomach and intestine inner layers as a 
result of infection by bacteria or viruses. The most common symptoms of gastro-
enteritis are diarrhoea and vomiting. Therefore, gastro-enteritis may reduce the 
absorption of anti-TB drugs as a result of decreased contact time between the drug 
and the intestinal microvilli. 
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2.4.5.2 Diarrhoea 
Diarrhoea is the passing of frequent, loose and watery stools, and it affects the 
absorption of drugs by enhancing gastro-intestinal motility, which reduces the 
resident time of drugs in the intestines and hence the absorption of drugs is 
reduced in general. Ethionamide, one of the drugs used in treatment of MDR-TB, 
produces intense gastrointestinal effects such as diarrhoea, nausea and vomiting 
(Arbex et al., 2010). Diarrhoea, as stated above, can increase the gastric motility 
of MDR-TB drugs, leading to reduced resident time in the intestine, decreasing 
their absorption. 
 
2.4.5.3 Malabsorption syndrome 
Malabsorption syndrome refers to difficulty in digesting nutrients from food as a 
result of shrinkage of the intestinal villi. Selective malabsorption of more than one 
anti-TB drug used in the treatment regimen could promote drug resistance. 
 
2.4.5.4 Hepatitis and cirrhosis of the liver  
Hepatitis, liver failure and cirrhosis of the liver can alter the PK of drugs 
biotransformed by the liver. Hepatic blood flow and liver enzyme activity, which 
are the primary determinants of the ability of the liver to metabolise drugs, can be 
affected by liver disease. For drugs susceptible to first-pass effect, the higher the 
blood flow to the liver, the greater the proportion of drugs metabolised by the 
liver and the lower the concentration of drugs in circulation, leading to reduced 
bioavailability of the drug. In addition, liver disease is characterised by decreased 
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protein binding and occurs with drugs that are highly bound to plasma proteins 
(Bremier, 1987). 
 
Hepatitis is defined by the presence of inflammatory cells in the tissue of the liver. 
Triggers of inflammation of the liver include viruses, toxic substances (such as 
alcohol, certain medications and chemicals), infections and autoimmune disease. 
Anti-TB drugs that can cause hepatitis include pyrazinamide, RIF and INH 
(Thompson et al., 1995). In acute viral hepatitis, symptoms are usually serious and 
last for a period of three to four weeks. Here, changes in drugs PK are less than in 
chronic hepatitis, and hepatic elimination returns to normal as the disease resolves 
(Bremier, 1987). In chronic hepatitis, which normally lasts longer than six weeks, 
there is increased hepatic clearance of highly metabolised drug as a result of 
decreased serum albumin concentration.  
 
Cirrhosis of the liver arises as a result of chronic liver disease and is characterised 
by scarring of the liver tissue, fibrosis and regenerated nodules, leading to liver 
dysfunction. Cirrhosis of the liver is generally caused by viruses, hepatitis B and 
C, alcoholism and fatty liver disease. In severe cases, decreased protein binding 
may occur due to reduced serum concentration of albumin. Thus, decreased 
protein binding may give rise to an elevated volume of distribution and this may 
prolong the elimination t1/2 of the drug bounded to the plasma protein (Bremier, 
1987).  
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Although high systemic bioavailability of a drug administered orally can occur 
due to reduced enzyme activity, it has also been suggested that increased 
bioavailability of an orally administered drug can arise as a result of the presence 
of portal-systemic shunting in cirrhosis of the liver (Bremier, 1987). Portal-
systemic shunting is characterised by a partial bypass of the liver of blood 
containing absorbed drug. In patients with extensive shunting and severe liver 
dysfunction, this partial bypass of the liver could result in almost complete 
bioavailability of the administered drug (Bremier, 1987). Furthermore, hepatic 
blood flow may be reduced in patients with cirrhosis of the liver as a result of 
scarring within the cirrhotic liver. The consequence is the reduced systemic 
clearance of drugs highly metabolised by the liver (Bremier, 1987).  
 
Liver failure is the deterioration of liver function as a result of liver damage, 
which can alter the binding of a drug to plasma proteins. Here, the amount of 
plasma protein is decreased, which would lead to a higher fraction of unbound 
drug and consequently a greater therapeutic effect. 
 
Drug-induced hepatotoxicity reduces the metabolic rates of most drugs due to 
damage to liver cells and liver microsomal enzymes, leading to increased 
bioavailability of drugs and possibly toxic effects of drugs (Rodghiero, 2000). 
Hepatotoxicity caused by ethionamide, for example, influences its metabolism by 
preventing microsomal enzymes, leading to a high fraction of the administered 
dose that reaches systemic circulation (Weyer et al., 2004). 
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2.4.5.5 Congestive cardiac failure  
Congestive cardiac failure is a disease characterised by a decrease in cardiac 
output and a decrease in renal and hepatic blood flow and as a result, renal and 
hepatic insufficiencies. In case of renal failure, the decrease in glomerular 
filtration rate (GFR) can cause the accumulation of drugs that depend on renal 
elimination for clearance. The reduced renal excretion of drugs may lead to the 
accumulation of drug in plasma and consequently to having drugs toxic effects. 
Tubular secretion or active transportation into the urine contributes to the 
elimination of many anti-bacterials such as B-lactam antibiotics. The blockage of 
the active transportation of anti-bacterials as a result of competition may prolong 
their half-life (t1/2).  Congestive cardiac failure can also impair hepatic drug 
metabolism by altering the metabolic capability of liver and influencing the rate of 
drug delivery to the liver via hepatic blood flow. Furthermore, congestive cardiac 
failure may also decrease the absorption of drugs by reducing gastric emptying or 
decreasing blood flow to the site of drug absorption in the small intestine. This 
will lead to the decreased plasma concentration of drugs. 
 
2.4.5.6 Renal disease 
Some diseases affecting the kidney alter plasma protein levels and contribute 
significantly to changes in drug-protein binding. These diseases can be HIV 
induced and include nephritic syndrome and HIV-associated glomerular-nephritis. 
Renal disease can be drug induced or caused by conditions such as shock, 
pyelonephritis, diabetes, urinary tract obstruction or hypertension.  
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Renal dysfunction has an effect on the metabolism of drugs. Most drugs are first 
transformed into metabolites before being excreted. Renal failure may not only 
prevent the excretion of these metabolites, but in some cases alters the metabolic 
clearance of drugs.  
 
In general, impaired renal function has been reported to alter the plasma-protein 
binding and tissue-protein binding of drugs. The resultant effect is the altered 
bioavailability of drugs that are susceptible to plasma or tissue binding. 
 
2.4.5.6.1 Plasma-protein binding 
In addition to the altered bioavailability of drugs that are susceptible to plasma or 
tissue binding, impaired renal function is associated with notable changes in the 
plasma-protein binding of some drugs. According to a study by Rodighiero 
(2000), it was found that for every acidic drug studied, serum-protein binding in 
uremic patients was decreased. The reason for the decreased binding was 
suggested to be as a result of acidic drugs binding to albumin, which plays a role 
in the distribution volume of acidic drugs. 
 
The decreased protein binding that arises in a case of renal impairment has been 
attributed to reductions in the level of serum albumin, structural changes in 
binding sites or the competitive displacement of drugs from albumin binding sites 
by organic molecules, resulting in increased Vd of these drugs (Atkinson, 2000). 
The increased Vd of these drugs might lead to unwanted side effects in patients. 
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2.4.5.6.2 Tissue binding of drugs 
Impaired renal function might cause an alteration in the tissue binding of drugs, 
which may affect the PK of drugs, especially those with a high apparent Vd 
(Atkinson, 2000). The reduced tissue binding of drugs might lead to a high 
volume of distribution of drugs and the increased clearance of drugs susceptible to 
tissue binding. The resultant effect is reduced therapeutic benefit of the drugs. 
 
2.4.5.7 Human immunodeficiency viral infection 
HIV-infected patients have been noted as having as much as a 70% decrease in 
serum drug concentration when compared with controls, although non-absorbers 
have also been identified within non-HIV patients (Douglas and Mcleod, 1999).  
 
In a study conducted by Peloquin et al. (1993), low CD4 count was indicative of 
malabsorption, but this was not seen in patients with AIDS who were co-infected 
with TB (Peloquin et al., 1993), although in a later study by Peloquin et al. (1996) 
it was found that serum peak concentrations of anti-TB drugs were lower in TB 
patients co-infected with HIV and having a CD4 cell count of <200 cell/mm
3
 
(Peloquin et al., 1996; Budha et al., 2008). 
 
When there is poor absorption of one or more drugs in a TB treatment regimen, 
sub-therapeutic concentration could enhance the possibility of resistance 
developing to other drugs in the regimen of TB therapy (Peloquin, 2002). Using 
serum-concentration response data, it was confirmed that the reduced 
bioavailability of anti-mycobacterial drugs could have serious consequences, such 
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as delayed or incomplete response to treatment or the selection of drug resistance 
for HIV-positive patients co-infected with TB (Choudri et al., 1997). Furthermore, 
second-line anti-TB drugs such as pyrazinamide and terizidone are less effective 
than INH and RIF; hence, patients on MDR-TB therapy may be at a greater risk of 
poor treatment response if malabsorption occurs. 
 
It has also been suggested that patients infected with HIV with or without 
diarrhoea may not sufficiently absorb anti-TB drugs. The study published by 
Gurumurthy et al. (2004) reported that HIV-infected patients with or without TB 
had lower plasma concentrations of RIF and INH well below the therapeutic 
range. In addition, it was stated that malabsorption of pyrazinamide and 
ethambutol was evident in HIV-positive patients co-infected with TB when 
compared to HIV-infected patients without TB (Gurumurthy et al., 2004). 
 
Some studies have suggested that malabsorption of anti-mycobacterial drugs 
occurs in HIV-infected patients with advanced HIV infection (Patel et al., 1995; 
Berning et al., 2003; Gurumurthy et al., 2004). This resulting lower anti-TB drug 
exposure may result in acquired drug resistance and the reduced efficacy of anti-
TB therapy in patients infected with HIV (Gurumurthy et al., 2004). 
 
2.4.6 Drugs with side effects that may affect the pharmacokinetics of anti-
tuberculosis drugs 
ARVs with gastro-intestinal side effects may potentiate similar side effects in 
patients receiving MDR-TB treatment. The selective malabsorption of more than 
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one anti-TB drug used in the treatment regimen could promote drug resistance. 
Ethionamide produces intense gastrointestinal effects such as diarrhoea, nausea 
and vomiting. Diarrhoea, as stated above, can increase the gastric motility of 
ethionamide, leading to reduced resident time in the intestine, decreasing its 
absorption. In addition, diarrhoea is the major side effect of protease inhibitors 
that can reduce the bioavailability of anti-TB agents. 
 
Nephrotoxicity as a result of the prolonged administration of nephrotoxic drugs 
such as vancomycin, and the co-administration with other toxic drugs, especially 
aminoglycosides, may result in the accumulation of anti-TB drugs in kidney 
tubules, leading to a longer half-life, which could be deleterious in patients. 
 
Hepatotoxicity induced by ethionamide can cause liver injury. When major liver 
damage occurs, as evidenced by jaundice, with a prolonged elevation of 
transaminases during a period of six to eight weeks, ethionamide administration 
should be stopped. Ethionamide should be carefully monitored in patients with 
liver disease, diabetes, alcoholism or mental instability. (Weyer, 2004). 
 
2.5 Interaction between anti-retroviral drugs and anti-tuberculosis drugs  
Due to the susceptibility of HIV-infected individuals to numerous opportunistic 
infections, they usually receive a wide variety of drugs in addition to their ARV 
therapy (De Maat et al., 2003). HIV-positive patients taking ARVs and co-
infected with TB have an additional problem of drug–drug interactions. For 
example, non-nucleoside reverse transcriptase inhibitors and protease inhibitors 
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are metabolised by CP450 and there is a significant PK drug interaction when 
they are administered concurrently with other drugs metabolised via the same 
enzyme pathway (Burman et al., 1999; De Maat et al., 2003). TDM should 
therefore be used to establish the adequacies of anti-TB drug doses and ARV drug 
doses, particularly protease inhibitors (PIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (Peloquin, 2002). 
 
Furthermore, HIV-infected patients tend to be more susceptible to adverse 
reactions such as peripheral neuropathy, cutaneous reactions, renal toxicity and 
gastro-intestinal disturbances (Weyer, 2005). Diarrhoea is one of the most 
common gastro-intestinal disturbance symptoms reported in HIV-positive patients 
and may result in drug malabsorption (Gurumurthy et al., 2004). The 
malabsorption of MDR-TB drugs has been reported in patients with HIV-related 
enteropathology (Weyer, 2005). 
 
Studies demonstrating interactions between second-line drugs that are used in 
MDR-TB treatment regimens and ARVs are still very few in numbers, although 
the potential for adverse interactions is considerable. TDM of drugs used in TB 
management is supported as TDM helps in better control of TB treatment, 
particularly in patients co-infected with HIV and in managing anti-TB drugs 
interactions (Peloquin, 2002). 
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2.5.1 Interaction between tenofovir and kanamycin 
The South African public sector ARV treatment guidelines have recently been 
changed to include tenofovir in the first-line regimen (National Department of 
Health, 2010). Drugs from the aminoglycoside class such as kanamycin are part of 
the MDR-TB treatment regimen in the South African tuberculosis programme. 
The aminoglycosides are potent nephrotoxins, in part due to the high 
concentration they attain in proximal convoluted tubular cells. Like 
aminoglycosides, tenofovir also attains high concentrations in proximal 
convoluted tubular cells as a result of active uptake into these cells (Kenyon et al., 
2011). According to Kenyon et al. (2011), a substantial proportion of patients 
taking tenofovir may develop certain of the features of Fanconi’s syndrome (a 
proximal tubular wasting syndrome as a result of proximal convoluted tubular 
cells dysfunction). 
 
Aminoglycosides are nephrotoxic, producing renal impairment. Patients taking 
amikacin are more likely to develop nephrotoxicity than patients taking 
streptomycin (Arbex et al., 2010). Tenofovir may also cause renal failure. Reports 
show that tenofovir is associated with mild decreases in GFR when compared 
with patients on other ARVs (National Department of Health, 2010). 
 
2.5.2 Interaction between alcohol and drugs 
Alcohol can interact with many medications, causing reduced effectiveness of 
administered medications and increased risk of illness, injury or death by altering 
the bioavailability of medications. Acute consumption of alcohol inhibits the 
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metabolism of a drug by competing with the drug for the same metabolising 
enzymes. This interaction increases the drug’s bioavailability and could potentiate 
the risk of unwanted side effects of the drug administered. However, a chronic 
dose of alcohol may induce a drug’s metabolising enzymes, thus decreasing the 
bioavailability of the drug and diminishing its effects. Even in the absence of 
alcohol, the enzymes activated by alcohol are available in the blood stream and 
impair the metabolism of susceptible drugs. 
 
2.6 Overview of laboratory findings on renal and liver function 
2.6.1 Renal function tests 
Renal or kidney function is generally assessed by measuring serum creatinine, 
urea concentration levels, or circulation of the GFR (Lamb, 2007). The GFR is 
widely used as the best indicator of kidney function because it makes possible the 
detection and classification of chronic kidney disease (Stevens et al., 2006; 
Lascano et al., 2010). In practice, the GFR is difficult to measure, therefore serum 
creatinine is used by clinicians to determine it (Levey et al., 1999). Kidney 
function ranges from normal GFR, >90 ml/min, to renal failure, GFR <15 ml/min 
(DiPiro et al., 2008).  
 
Creatinine is a by-product of muscle breakdown and is filtered out of the blood by 
the kidney. There is almost no reabsorption of creatinine by the renal tubules, so 
any dysfunction in the ability of the kidney to filter results in a build-up of 
creatinine in the blood. Creatinine levels in the blood can be used to determine 
creatinine clearance, which indicates the GFR. The use of serum creatinine alone 
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presents some limitations, and in order to overcome them, equations for 
estimating the GFR take into account variables such as gender, age, race and body 
weight (Levey et al., 1999; Stevens et al., 2006).  
 
The Cockcroft-Gault formula for estimating the GFR is commonly used and takes 
into account serum creatinine, body weight and an adjustment factor for gender 
(Simon et al., 2011). In addition, the Cockcroft-Gault formula over-estimates the 
GFR due to the active secretion of creatinine in the renal tubules (Stevens et al., 
2006). Furthermore, this formula does not give room for the adjustment of body 
surface area, but relies solely on individual body weight, which could be 
misleading. 
 
Another method for estimating the GFR is using the modification of diet in renal 
disease (MDRD) method. The MDRD formula adjusts for body surface area (1.73 
m
2
), age, gender and race. This is because the muscle mass of women is lower 
compared to that of men. Also, the black race tends to have an increased muscle 
mass when compared to the white population. The major limitation of the MDRD 
equation is that it is likely to under-estimate GFR at higher ranges (>60 
ml/min/1.73 m
2
) of kidney function (Stevens et al., 2006; Simon et al., 2011). 
However, the MDRD formula is a widely accepted and preferred method in 
evaluating the GFR as compared to previously used methods (Stevens et al., 2006; 
Lascano et al., 2010; Aggarwal et al., 2011). 
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2.6.1.1 Risk factors that might impair kidney function 
Several factors contribute to the loss of kidney function in patients. They include 
drug-induced renal toxicity, HIV and co-existing diseases. The epidemiology of 
chronic kidney disease is rising in the world, and sub-Saharan Africa is 
considered to have the highest burden (Retnakaran et al., 2006). The rise of 
chronic kidney disease in South Africa is associated with the surge of diabetes and 
hypertension, which are potential triggers of the disease, together with the burden 
of HIV. Hypertension is believed to be a trigger of end-stage renal disease in 
34.6% of blacks, 4.3% of whites, 20.9% of mixed-race (coloured) people and 
13.9% of Indians in South Africa (Katz, 2005). In addition, diabetes is considered 
to occur in 10–16% of South Africans (Katz, 2005). 
 
2.6.1.1.1 Human immunodeficiency virus-related kidney dysfunction 
The introduction of highly active ARV therapy has helped in reducing the 
epidemiology of kidney disease in HIV-positive patients; however, kidney disease 
still remains a major cause of mortality and morbidity among the HIV-infected 
population (Cianflone et al., 2010).  
 
HIV can infect the kidneys, as presented by HIV-associated nephropathy, which is 
evident by a rapid decline in renal function, lower CD4 count and proteinuria 
(Jeremy et al., 2008) due to HIV directly infecting renal cells (Gerntholtz et al., 
2006). A study done in Soweto, South Africa, reported that HIV-positive patients 
exhibited HIV-associated nephropathy at any stage of HIV infection and had 
varying degrees of GFR and proteinuria (Gerntholtz et al., 2006). In addition, 
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acute kidney failure is known to be a complication of HIV infection in patients 
taking highly active ARV therapy. Acute kidney failure is defined as a rapid 
decrease in GFR in patients with previously normal kidney function or in patients 
with pre-existing chronic kidney disease (Roe et al., 2008). It was reported that 
acute kidney failure is manifested within three months after the commencement of 
highly active ARV therapy, commonly in patients with advanced HIV infection 
and in those with co-existing opportunistic infections (Roe et al., 2008).  
 
2.6.1.1.2 Antiretroviral-induced nephrotoxicity 
The adverse effects of ARVs account for 14% of acute kidney injury occurring 
after three months of commencing highly active ARV therapy and are usually 
reversible once the offending drug is discontinued (Roe et al., 2008; Kalyesubula 
and Parazella, 2011). Nucleoside reverse transcriptase inhibitors (NRTIs), such as 
zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and 
emtricitabine, cause kidney toxicity, which is exhibited as lactic acidosis. 
Didanosine might cause electrolyte imbalance, which is manifested as 
hypokalaemia, hyponatremia, hypermagnesemia and hyperuricemia, and 
stavudine may cause hyperuricemia (Kalim et al., 2008). Tenofovir is an NRTI 
and has a potent tendency to cause kidney dysfunction.  
 
Female HIV-positive patients with pre-existing kidney disease, undergoing 
prolonged treatment with ARVs, experiencing elevated serum creatinine 
concentration and co-administration of other nephrotoxic drugs, and with a CD4 
count of <200 cells/mm
3
 are more likely to present with tenofovir-related kidney 
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toxicity (Roe et al., 2008; Cianflone et al., 2010; Kalyesubula and Parazella, 
2011). PIs such as indinavir are potent inducers of acute kidney injury. Ritonavir, 
which is in the same class of ARV as indinavir, has the potential to cause kidney 
injury. Reports show that about 70% of tenofovir-related cases of induced 
nephrotoxicity are observed with the co-administration of low doses of ritonavir 
(Roe et al., 2008; Kalyesubula and Parazella, 2011). Among the NNRTI class of 
ARVs, nevirapine has the most potential to cause kidney toxicity, which presents 
as lactic acidosis. 
 
Furthermore, older age was established as an independent risk factor in causing a 
reduction in serum creatinine concentration among HIV-infected individuals 
(Cianflone et al., 2010). It was also published that pre-existing AIDS and a history 
of a low CD4 count are potential factors in the alteration of kidney function 
(Cianflone et al., 2010). 
 
2.6.1.1.3 Co-existing diseases 
Previous studies have defined co-existing diseases as an important risk factor for 
developing kidney dysfunction in patients infected with or without HIV. Hepatitis 
C virus co-infection has been confirmed as contributing to kidney disease (Roe et 
al., 2008). Hypertension is a leading cause of kidney disease and kidney failure. It 
can damage blood vessels in the kidney, making the elimination of wastes and 
fluids from the body difficult. In addition, kidney dysfunction is common in 
patients with type-2 diabetes. Loss of kidney function in these patients occurs at 
the early stage of diabetes due to micro-albuminuria (Retnakaran et al., 2006). 
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Micro-albuminuria is characterised by small amounts of protein albumin in the 
urine and is clinically used as an indicator of kidney dysfunction (Retnakaran et 
al., 2006). 
 
2.6.1.1.4 Co-administered drugs 
Certain medications are implicated in kidney dysfunction. Some examples include 
aminoglycoside antibiotics, acyclovir, amphotericin B, amitriptyline, fluoxetine, 
non-steroidal anti-inflamatory drugs and anti-depressants, among others. Risk 
factors for drug-induced nephrotoxicity include older age, pre-existing renal 
insufficiency, sepsis, volume depletion and diabetes (Roe et al., 2008). 
Nephrotoxicity due to drugs is usually reversible once the offending drug is 
withdrawn. 
 
2.6.2 Liver function tests 
The primary function of the liver is drug metabolism. The healthy liver transforms 
drugs to biologically active forms via the CP450 enzyme pathway (Aaron et al., 
2004; Puoti et al., 2009). Also, the liver detoxifies the blood of damaging 
chemicals and metabolites (Kaplowitz, 2004; Puoti et al., 2009). Alanine 
aminotransaminase (ALT) and aspartate aminotransaminase (AST) are generally 
used as biomarkers of liver injury (Puoti et al., 2009; Aragon et al., 2010). ALT 
has the highest concentration in the liver when compared to other organs in the 
body, which makes it the most specific indicator of liver injury. AST is present in 
many tissues of the body, such as muscles and the brain. Gamma glutamyl 
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transpeptidase is found in liver and biliary epithelial cells and is the most specific 
marker of hepatobilary disease. 
 
Another method used to determine the severity of liver disease is Child-Pugh 
score. The Child-Pugh scoring system has been a common application in 
evaluating the risk of developing liver disease and the chances of recovery or 
survival. It employs a grading scale to classify liver disease. Based on this 
classification, mild liver disease (class A) falls in the range of 5-6 points, 
moderate (class B) falls between 7 and 9 points and severe (class C) is between 10 
and 15 points (Chatzicostas et al., 2003). 
 
2.6.2.1 Risk factors that might elevate the level of liver enzymes 
Biomarkers of liver injury such as ALT and AST are elevated in certain diseases, 
while certain medications have the potential to raise the serum level of liver 
enzymes. HIV-positive patients taking ARVs might have an elevation in their 
liver enzymes (Gisolf et al., 2000), and this is the common cause of mortality and 
morbidity in patients infected with HIV (Soriano et al., 2008).  
 
2.6.2.1.1 Human immunodeficiency virus-related liver disease 
 
For patients with HIV infection, liver disease contributes to greater morbidity, 
higher costs of care, and increased risk of liver failure and death (Puoti et al., 
2009). Lymphoma, Kaposi’s sarcoma and bilary duct disease are examples of 
liver diseases and intrahepatic opportunistic infections that occur commonly in 
 
 
 
 
42 
 
HIV-infected patients (Leucuta and Nlase, 2006) and they can alter the PK of 
administered drugs.  
 
Liver failure and liver-related death have been described mainly in patients with 
higher liver enzyme elevation. HIV-positive patients take a combination of ARVs 
and almost every ARV has been implicated in liver enzyme elevations (Soriano et 
al., 2008; Puoti et al., 2009). Nevirapine and, less frequently, efavirenz have been 
found to increase gamma glutamyl transpeptidase serum levels (Clarke et al., 
2002; Soriano et al., 2010) 
 
2.6.2.1.1 Antiretroviral disease-induced hepatotoxicity 
The risk of ARV-induced liver injury increases with NNRTIs, which have the 
highest incidence, followed by PIs and NRTIs (Puoti et al., 2009). NNRTIs such 
as nevirapine, efavirenz and enfuvirtide induce liver injury by provoking allergic 
reactions in HIV-positive patients. Symptoms of allergy are evident within a few 
days to eight weeks after the commencement of treatment and they include a rash, 
fever, fatigue and gastro-intestinal symptoms such as nausea, vomiting, abdominal 
pain and diarrhoea. Protease inhibitors are less implicated in serious liver-related 
side effects (Puoti et al., 2009). Ritonavir has been found to be more hepatotoxic 
when administered in full dose compared to other drugs in the same class (Soriano 
et al., 2008).  
 
NRTIs have been found to cause mitochondrial toxicity that could result in lactic 
acidosis and hepatic steatosis (Clark et al., 2002, Soriano et al., 2008). 
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Mitochondrial toxicity occurs after prolonged NRTI treatment and result when 
drugs in the NRTI class interfere with the synthesis of mitochondrial DNA. 
NRTIs that are associated with mitochondrial toxicity include zalcitabine, 
didanosine, stavudine, zidovudine and abacavir, in descending order of potency 
(Soriano et al., 2008; Heil et al., 2010). 
 
2.6.2.1.3 Co-existing diseases 
Apart from HIV, other co-existing diseases in patients might elevate serum liver 
enzymes. Some of these diseases include alcohol-related liver disease and chronic 
viral hepatitis. Alcohol-related liver disease is characterised by a rise in ALT and 
AST levels, that is, if the AST level is two to three times higher than the normal 
value, together with a history of excessive alcohol use in patients. Chronic viral 
hepatitis is characterised by a minimal rise in ALT and AST levels, that is, two to 
three times higher than the upper limit (Aragon et al., 2010). 
 
2.6.2.1.4 Co-administered drugs 
Drug-induced liver injury includes the induction of hepatic enzymes, such as in 
the case of anti-epileptics, hypersensitivity reactions, idiosyncratic reactions and 
auto-immunity. Non-steroidal anti-inflammatory drugs and penicillin-derived 
antibiotics are also implicated in drug-induced liver injury. In patients with liver 
failure, aminoglycosides can be administered at full doses; however, patients with 
severe liver failure should be screened for co-existing hepatorenal syndrome 
(Arbex et al., 2010).  
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2.7 Kanamycin pharmacology and pharmacokinetics 
2.7.1 Overview 
Kanamycin is a bactericidal agent and belongs to the aminoglycoside antibiotic 
group. The structure of aminoglycosides consists of two or more aminosugars 
linked by glycosidic bonds to an aminocyclitol component. They are highly water 
soluble because of the many amino and hydroxyl groups in their chemical 
structure. 
 
2.7.2 Kanamycin anti-microbial spectrum of activity and mechanism of action 
Kanamycin exerts its effect by binding to the 30S sub-unit of bacterial ribosomes, 
thus leading to a reduced mRNA reading and, finally, impaired protein synthesis 
(Perri and Bonora, 2004). Bactericidal activity has been categorised as either 
concentration dependent or time dependent. Kanamycin has a concentration-
dependent bactericidal activity because its rate of bacterial killing increases as its 
concentration increases over a wide range of concentration (Nuermberger and 
Grosset, 2004). Kanamycin exhibits non-saturable concentration-dependent 
killing (Arbex et al., 2010), which means that it is effective even when its serum 
concentrations are below the minimum inhibitory concentration (MIC).  
 
2.7.3 Activity against Mycobacterium tuberculosis 
Kanamycin has potent bactericidal activity against rapidly dividing mycobacteria 
and has little or no activity against non-replicating bacilli in the stationary or 
sterilising phase of growth (Perri and Bonora, 2004). Kanamycin is not effective 
against intracellular bacteria because it does not penetrate mammalian cells and, 
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as a result, it is used only in the bactericidal phase. For a drug to be used in the 
stationary or sterilising phase, it must be active against intraphagocytic and slowly 
dividing mycobacteria. This is the rationale of using kanamycin only in the 
bactericidal phase, when a large number of replicating mycobacteria are present at 
extra-cellular level (Perri and Bonora, 2004).  
 
Kanamycin exerts bacterial activity against MTB at a concentration of about 6 
µg/ml in vitro and shows rapid inhibitory effect at concentration above its MIC 
(Nuermberger and Grosset, 2004). Kanamycin’s activity relies on a high 
Cmax:MIC ratio (Douglas and Mcleod, 1999). For optimal anti-bacterial effects 
with kanamycin, a high Cmax in relation to MIC or a high extent of anti-microbial 
exposure as determined by the AUC of time versus concentration above the MIC 
is needed (Douglas and Mcleod, 1999). 
 
2.7.4 Pharmacokinetics of kanamycin 
Understanding the PK of kanamycin is important in determining the time course 
of anti-mycobacterial action and in optimising the dose of kanamycin in patients 
with MDR-TB and in those with MDR-TB and co-infected with HIV. 
 
2.7.4.1 Absorption 
Kanamycin is inadequately absorbed from the gastro-intestinal tract. When 
kanamycin is administered orally or rectally, less than 1% of its dose is absorbed 
(Budha et al., 2008). The oral absorption of aminoglycosides is minimal because 
aminoglycoside antibiotics are very hydrophilic and poorly lipid soluble 
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compounds. Due to kanamycin’s polar nature, it is not used in the maintenance 
phase of MDR-TB treatment because its penetration into cells is poor and its 
distribution limited to extra-cellular spaces (Budha et al., 2008). As a result, it is 
administered parenterally (Coyne et al., 2009). The absorption of kanamycin is 
complete when administered intramuscularly and the serum levels peak within 
30–90 minutes (Budha et al., 2008).   
 
2.7.4.2 Distribution 
Aminoglycosides exhibit low protein binding (approximately 10%) (Pechere and 
Dugal, 1979; Arbex et al., 2010). The distribution of aminoglycosides is limited to 
extracellular spaces, which makes them to act only on extra-cellular bacilli. 
 
2.7.4.3 Metabolism and elimination  
Most of the enzymes that catalyse the metabolism of foreign compounds in the 
body are intracellular and since aminoglycosides do not penetrate most 
mammalian cells, they do not undergo significant metabolism. 
 
The elimination of aminoglycosides is primarily by the kidneys (Arbex et al., 
2010). About 80–98% of kanamycin is excreted unchanged by the kidneys over a 
24-hour period with a serum half-life of about 4 hours (Coyne et al., 2009): 1% is 
excreted in bile and 1% in faeces (Arbex et al., 2010). This means that 
kanamycin’s excretion may be prolonged in renal-impaired patients (Budha et al., 
2008): its elimination half-life increases from 107 minutes in younger individuals 
to 282 minutes in elderly populations (Holdiness, 1984). 
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2.7.5 Kanamycin drug interactions 
There is a possible risk of drug interactions when administering amphotericin B, 
vancomycin, cephalosporin, cisplatin and loop diuretics such as furosemide 
concurrently with aminoglycosides (Arbex et al., 2010). In addition, concomitant 
administration of aminoglycosides and neuromuscular blocking agents can cause 
respiratory depression, and patients with conditions such as myasthenia gravis, 
hypocalcemia, severe hypokalemia or hypomagnesemia are susceptible to such 
side effects (Arbex et al., 2010). 
 
2.7.6 Side effects of kanamycin and precautions 
Ototoxicity and nephrotoxicity are the most important clinical side effects of 
aminoglycosides. These effects are related to the duration and dosage of 
aminoglycosides and are most likely to occur in older individuals, dehydrated 
patients or those suffering from kidney diseases (Arbex et al., 2010). 
 
Since aminoglycosides are majorly eliminated by the kidneys, they produce 
kidney toxic effects due to their accumulation in the kidney tubules (Arbex et al., 
2010). Such effects are common in patients with a history of kidney disease and in 
elderly patients. Therefore, in patients with a creatinine clearance of <30 ml/min, 
the dose of kanamycin should be adjusted to 12–15 mg/kg/day administered two 
to three times a week (Bennett et al., 1977; Arbex et al., 2010). Thus, TDM, 
which involves the measurement of drug concentration in plasma, can enable 
dosage adjustment in patients with renal insufficiencies. By measuring drug levels 
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in the blood at intervals, TDM maintains TB drugs’ plasma concentration within 
the therapeutic range (Taft, 2009).   
 
The most severe side effect caused by aminoglycosides is ototoxicity (Arbex et 
al., 2010). The risk is high in the elderly, in patients undergoing prolonged periods 
of treatment and those receiving high doses of kanamycin. Other side effects of 
kanamycin include hypersensitivity, respiratory depression and neurotoxicity. 
 
2.7.7 Clinical uses 
Kanamycin is an antibiotic with a broad spectrum of activity against some gram-
positive and gram-negative organisms. Kanamycin is active against aerobic 
bacilli, but not against anaerobic organisms, because oxygen pathway is necessary 
for the activity of kanamycin. 
 
2.7.8 Resistance to aminoglycosides 
The presence of sub-optimal concentrations of a drug tends to select for drug-
resistant organisms. Under these circumstances, mutant strains that possess a 
degree of resistance are favoured and tend to dominate the bacteria population. 
Therefore, in order to prevent the development of resistance, it is best to pay 
careful attention to dosing. For aminoglycosides, a high Cmax:MIC ratio correlates 
best with anti-bacterial activity (Nuermberger and Grosset, 2004). 
 
Since the mechanism of action of aminoglycosides is the binding to the 30S sub-
unit of bacterial ribosomes, any changes in ribosomal proteins either via mutations 
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or enzymatic modification would reduce aminoglycoside binding and therefore 
enhance the rapid selection of resistance within the bacteria population (Davies 
and Wright, 1997). Another mode of resistance of aminoglycosides is reduced 
uptake and accumulation of aminoglycosides in bacteria. 
 
2.7.9 Pharmacokinetic parameters of Kanamycin 
Although several studies have reported the PK parameters of kanamycin in 
healthy volunteers, studies on the plasma PK of kanamycin in patients infected 
with MDR-TB are still very scarce, particularly in South Africa. 
 
2.7.9.1 Pharmacokinetics in healthy volunteers 
Many studies have described the PK of kanamycin in healthy volunteers (Cronk 
and Naumann, 1959; Cabana and Taggart, 1973; Doluisio et al., 1973; Clarke et 
al., 1974; Kirby et al., 1976; Coyne et al., 2009) using both intravenous and 
intramuscular routes of administration and different doses. These studies show 
that the PK parameters of kanamycin are independent of the route of 
administration and are fairly reproducible in the same healthy individuals at 
different times (Pechere and Dugal, 1979). However, intramuscular administration 
of kanamycin is preferred, since the repeated high peaks obtained after 
intravenous administration are avoided (Pechere and Dugal, 1979).  
 
The previous studies on kanamycin in healthy volunteers shows that its PK vary 
with age and renal function (Douglas and Mcleod, 1999), and its maximum 
plasma concentration does not increase with increasing age and is not influenced 
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by birth weight; however, clearance is directly dependent upon birth weight and 
post-natal age (Holdiness, 1984). Kanamycin peak serum concentration occurs 
within 1 hour of an intramuscular dose (Douglas and Mcleod, 1999), because a 
dose of 7.5 mg/kg results in peak serum levels of 20–35 µg/ml (Budha et al., 
2008).   
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Table 2.3: Kanamycin pharmacokinetic parameters in healthy volunteers 
 
 
 
 
 
 
 
 
Dose Subjects Cmax 
(µg/ml) 
Tmax (hr) T1/2 
(hr) 
AUC 
(µg/ml/
hr) 
Ke  (hr-
1
) 
Vd 
(L) 
Cltot 
(l/hr) 
Cl 
renal 
(l/hr) 
F Reference 
539 mg 
 
10 N/A N/A 2.3 
+/- 
0.1 
92 0.30 +/-
0.02 
22.4 
+/-2.7 
6.4 4.4 0.68 
+/-
0.07 
Doluisio et 
al. (1973) 
500 mg 10 N/A N/A 2.2 105 0.32 18.5 5.9 5.3 0.90 Cronk and 
Naumann 
(1959) 
1,000 mg 10 N/A N/A 2.7 192 0.26 20.6 5.3 4.5 0.84 Cronk and 
Naumann 
(1959) 
2,000 mg 20 N/A N/A 2.4 395 0.29 17.7 5.1 4.3 0.83 Doluiso et 
al. (1973) 
15 mg/kg N/A 22.5 N/A 4 N/A N/A N/A N/A N/A N/A Coyne et 
al. (2009) 
250 mg 12 11.9 0.80 2.1 44.2 N/A 21.7 N/A 7.9 0.84 Cabana 
and 
Taggart 
(1973) 
500 mg 12 20.6 1.0 2.3 90.0 N/A 23.6 N/A 7.13 0.77 Cabana 
and 
Taggart 
(1973) 
614 mg 4 18.0 2 2.0 N/A N/A N/A N/A N/A N/A Clarke et 
al. (1974) 
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As indicated in Table 2.3, F = bioavailability 
 
2.7.9.2 Pharmacokinetic parameters in patients with multidrug resistant 
tuberculosis 
Yew et al. (1999) presented a study on the serum PK of anti-mycobacterial drugs 
in HIV-negative patients with MDR-TB during therapy. In this study, serum 
samples of 13 patients with MDR-TB were taken 0, 1, 2, 4 and 8 hours after the 
administration of anti-mycobacterial drugs for assay of levels in order to gain 
insight into their basic PK. The drugs assessed were amikacin, kanamycin, 
ofloxacin, para-aminosalicyclic acid, prothionamide, cycloserine, pyrazinamide 
and ethambutol. The results from fluoroimmuno assay of kanamycin showed that 
after a dose of 15 mg/kg, Cmax was achieved at 30.94 +/-7.72 mg/L (mean +/-SD), 
Tmax was recorded at 0.5–1.5 hours, t1/2 was estimated to be 3.7 hours, the 
Cmax:MIC ratio was recorded as 8–16 and MIC was achieved within a range of 2–
4 mg/L (Yew, 1999). 
 
2.7.9.3 Pharmacokinetic-pharmacodynamic relationship of kanamycin 
Aminoglycosides have concentration-dependent bactericidal activity, therefore the 
goal of anti-mycobacterial therapy is to maximise the concentration of these 
antibiotics. PK parameters such as the AUC0-24: MIC ratio and Cmax: MIC ratio 
correlates best with the rate of bacterial killing (Nuermberger and Grosset, 2004). 
For kanamycin, the ideal dosing regimen would maximise concentration, because 
the higher the concentration, the higher the extent of bacterial killing. In order to 
optimise drug therapy, dosing strategies for kanamycin include the highest 
possible dose that does not lead to toxicity in order to maximise drug 
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concentrations and therefore the rate of killing at site of mycobacterial infections. 
For aminoglycosides, it is best to have a Cmax: MIC ratio of at least 8–10 to 
prevent resistance (Nicolau, 2003). 
 
2.7.9.4 How therapeutic drug monitoring may optimise the dose of kanamycin 
A standard dose of 15 mg/kg intramuscularly produce Cmax values of 35–45 µg/kg 
(Peloquin, 2002). According to Peloquin (2002), it is probable that repeated 
intramuscular injection may harden the tissue and alter the absorption of 
kanamycin over time, which may interfere with Cmax. Furthermore, kanamycin 
excretion is dependent on renal elimination. Thus, the adequacy of Cmax and the 
capability of the kidneys in excretion can be detected using the two- and six-hour 
sampling strategy. A dose increase is expected if peak concentration is less than 
75% of desired range (Peloquin, 2002). TDM may be useful to prevent further 
resistance in patients with MDR-TB and in those susceptible to drug–drug 
interactions that may complicate clinical situation (Peloquin, 1997). 
 
2.8 Overview of methods used for the determination of plasma 
concentrations of anti-tuberculosis drugs 
Several methods have been suggested by previous studies for the determination of 
concentrations of anti-mycobacterials in biological fluids. These methods could be 
qualitative, such as nuclear magnetic resonance spectroscopy, mass spectrometry 
and x-ray crystallography, or quantitative, like radio-chemical assay, 
microbiological assay, radio-immuno assay and enzyme-immuno assay. 
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Although X-ray crystallography, microbiological assay and enzyme-immuno 
assay are easy to use, they are not specific (La and Feng, 2007). HPLC methods 
are reliable and are widely utilised for the analysis of anti-mycobacterials. HPLC 
combined with MS analysis of anti-TB agents is rapid, sensitive and specific and 
could successfully be applied to TDM in TB patients (La and Feng, 2007). 
 
2.8.1 Liquid chromatography coupled with mass spectrometry 
The use of LC/MS has been developed and approved for the instantaneous 
quantification of anti-TB agents in human plasma (Brewer and Henion, 1998). 
The LC/MS technique is oriented toward the detection and identification of 
specific chemicals in the presence of other chemicals, for example, in a complex 
mixture (Brewer and Henion, 1998). In comparison to ultra-violet (UV) 
spectrometry, mass spectrometry is used in combination with HPLC due to high 
sensitivity and specificity as long as the drug to be analysed can be suitably 
ionised and analysis time is short.  
 
A large number of HPLC techniques coupled with UV, fluorometric or mass 
spectrometric for the determination of concentration of aminoglycosides and other 
antibiotics are contained in the literature (Niessen, 1998; Gennaro, Calvino and 
Abrigo, 2001; Khuhawar and Rind, 2002). Although HPLC coupled with UV and 
fluorescence detectors have provided satisfactory results, they have limited 
specificity, and thus it may be difficult to differentiate the analyte from its 
metabolites in a complicated mixture. Another reason why better analytical 
methods may be needed is that some very potent drugs are administered at low 
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doses and as a result are present at very low levels in biological matrices, making 
them difficult to detect in a complex mixture with other chemicals. Therefore, 
higher-specificity and -sensitivity capabilities are required, which are not provided 
by HPLC coupled with UV or fluorescence techniques in the analysis of drugs or 
their metabolites in biological mixtures. 
 
2.8.2 Previously used methods for determining kanamycin plasma 
concentrations 
Numerous methods have reported the analysis of aminoglycosides in a variety of 
biological samples such as tissue, milk, blood and urine (Kennedy et al., 1998; 
Brewer and Henion, 1998; Stead, 2000; Loffler and Ternes, 2003; La and Feng, 
2007). These methods include microbiological, radio-immuno and enzyme-
immuno assay. They are easily handled, but are not specific (La and Feng, 2007).  
 
2.8.2.1 Microbiological assays 
Microbiological assays have been widely used in the past to estimate the potency 
of anti-bacterials (Maitra et al., 1979; Stead, 2000). Potency is assessed by 
comparing a standard with the inhibition of growth of a specific micro-organism 
produced by known concentration of the antibiotic observed (Stead, 2000). 
Microbiological assays are appropriate for handling a large number of samples, 
while the equipment used is less sophisticated and relatively inexpensive. The 
basic method is the agar-diffusion assay (Maitra et al., 1979; Stead, 2000). 
However, due to the introduction of enzyme-multiplied-immuno assay technique 
(ELISA), there has been a considerable decline in the use of microbiological 
assays for the analysis of aminoglycoside over the past 20 years (Stead, 2000). It 
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was reported that there was inaccuracy in the determination of tobramycin by agar 
diffusion in comparison with ELISA and HPLC (Sachetelli et al., 1998). Another 
factor contributing to the reduction in the use of the agar diffusion method is the 
length of time taken before the results can be read (Stead, 2000). It takes more 
than six hours for results to be readable (Peng et al., 1977). 
 
2.8.2.2 Radio-immuno assay 
Radio-immuno assay is a quantitative method that has been used successfully in 
determining aminoglycosides in biological fluids (Maitra et al., 1979). This 
method involves a mixture of the free drug in the sample and a fixed amount of I-
labelled drug (tracer) (Stead, 2000). Antigen-antibody complex is precipitated 
when a second antibody is directed against the first antibody to achieve separation 
of the bound and free drug. The amount of radioactivity associated with the bound 
drug is measured using a gamma counter. Although radio-immuno assay is highly 
sensitive and specific, the equipment is expensive and cross-reactions between 
aminoglycoside antibiotics have been reported (Peng et al., 1977; Stead, 2000). 
 
2.8.2.3 Enzyme-linked immuno-sorbent assay 
In ELISA, an antigen binds to a solid immobilised surface and then conjugates 
with an antibody that is specific to an enzyme. ELISA can also be competitive or 
non-competitive assays (Stead, 2000). In competitive ELISA, antigen in a sample 
(free antigen) and plate-adsorbed antigen (bound) compete for the detection 
antibody. Competitive ELISA is developed for low molecular weight compounds 
such as aminoglycosides, because they possess only one antibody-binding site. In 
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non-competitive ELISA there is binding of antigen in the sample to an excess of 
detection antibodies.  
 
The use of ELISA to detect aminoglycosides is difficult due to low molecular 
weight compound adsorption to solid phases (Sachetelli et al., 1998). Also, in a 
study on the analysis of tobramycin it was recorded that ELISA and HPLC gave 
equal results, while analysis with microbiological agar diffusion was an 
overestimation of the initial quantity (Sachetelli et al., 1998).  
 
Furthermore, studies done on tobramycin using ELISA were not tested on samples 
with complicated matrices (Sachetelli et al., 1998). Hence, according to Stead 
(2000), it is not known whether ELISA would be appropriate for applications 
involving tissue or plasma, since many molecules in the sample would compete 
with the analyte for the non-specific binding site (Sachetelli et al., 1998). Another 
potential barrier in using ELISA for plasma or tissue samples is the specificity of 
enzyme properties. This may affect this type of assay and in some cases normal 
constituents of plasma may interfere with the assay. 
 
2.8.2.4 High-pressure liquid chromatography 
In PK studies, methodologies must provide high sensitivity and exceptional 
specificity, because the concentration-time curve determines how well a drug is 
being cleared by an individual and how well the analytical system is working 
(Want et al., 2003). HPLC currently meets the requirements for the determination 
of the plasma concentration of aminoglycosides (Stead, 2000). HPLC methods are 
 
 
 
 
58 
 
reliable and widely used for the analysis of aminoglycoside antibiotics; however, 
the major disadvantage of HPLC in the assay of aminoglycosides is the lack of 
chromophore or fluorophore, which makes them unsuitable for UV or 
fluorescence detectors (Stead, 2000). Therefore, it is essential that 
aminoglycosides are labelled with a chromophore or fluorophore tag by a 
chemically derivatised method, which is complex and time-consuming. Mass 
spectrometry is the method of choice for detecting aminoglycosides due to the 
lack of chromophore and fluorophore (Loffler and Ternes, 2003).  
 
2.8.3 Separation method for High-pressure liquid chromatography 
Aminoglycosides are very water-soluble compounds due to many amino and 
hydroxyl groups in their chemical structure (La and Feng, 2007). Due to the 
polarity and adsorption properties of these compounds, several challenges arise 
when using HPLC for chromatography differentiation of aminoglycosides (Loffler 
and Ternes, 2003). Since aminoglycosides are not retained by reversed-phase 
column because of their hydrophilic nature, a volatile agent is necessary for MS 
detection and this may be accomplished using perfluorinated carboxylic acids and 
ammonium salts (ion exchange) or heptafluorobutyric acid (ion pairing). Ion-
pairing HPLC is generally preferred to ion-exchange HPLC because it is more 
efficient, and control over selectivity and resolution is easier (Stead, 2000). 
 
2.8.4 Sample preparation for High-pressure liquid chromatography analysis 
The purpose of sample preparation for HPLC analysis is to concentrate the analyte 
from the matrix, leaving behind substances that may hinder the processes of 
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derivatisation, isolation and detection. Aminoglycosides are highly water-soluble 
molecules and are immiscible in water-insoluble liquid; therefore liquid-liquid 
extraction with organic solvent is difficult. Solid-phase extraction is appropriate 
for separating polar compounds (La and Feng, 2007). A number of solid-phase 
extraction columns are commonly used to extract aminoglycosides from 
biological samples (Peng et al., 1977; Keevil et al., 2003). 
 
In this study, LC/MS will be the preferred method in the quantification of 
kanamycin plasma concentration due to its high specificity and sensitivity 
compared to the other methods described above. 
 
2.9 Hypothesis 
2.9.1 Experimental hypothesis 
 There are differences in the PK parameters between HIV-positive and HIV-
negative patients 
 HIV influences the PK of kanamycin. 
 Changes in kidney function influence PK of kanamycin. 
 Interactions between ARVs and kanamycin affect the PK of kanamycin. 
 
2.9.2 Null hypothesis  
 There is no difference in the PK parameters of kanamycin between patients 
infected with MDR-TB (control group) and patients co-infected with MDR-TB 
and HIV (experimental group). 
 HIV does not influence the PK of kanamycin. 
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 Changes in kidney function do not influence the PK of kanamycin. 
 Interactions between ARVs and kanamycin do not affect the PK of kanamycin. 
    
2.10 Research questions 
Issues important to conceiving the research question were discussed in the 
literature review. These issues are summarised below. 
 
To the best of my knowledge, no previous study has investigated the PK of 
kanamycin in patients infected with MDR-TB and in those with MDR-TB co-
infected with HIV using LC/MS analysis or any other analytical method. 
Therefore, it would be interesting to determine the PK parameters of kanamycin 
in these patients using LC/MS and to find out if HIV changes the PK of 
kanamycin in MDR-TB patients co-infected with HIV. 
 
Secondly, we seek to find out whether the changes in kidney function that are 
common in patients suffering from MDR-TB and MDR-TB plus HIV infection 
have any influence on the PK of kanamycin. 
 
Thirdly, many of the patients with MDR-TB and co-infected with HIV are on 
ARV therapy, therefore we would like to find out if there is any interaction 
between ARVs and drugs used for MDR-TB treatment in patients infected with 
MDR-TB and HIV. 
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The study therefore attempts to answer the following questions: 
1. Is LC/MS a reliable method for the determination of kanamycin plasma 
concentrations? 
2. What are the PK parameters of kanamycin in patients with MDR-TB and in 
patients with MDR-TB co-infected with HIV? 
3. Could HIV infection influence the PK of kanamycin in MDR-TB patients? 
4. To what extent do changes in kidney function influence the PK of kanamycin? 
5. Do lamivudine, stavudine, efavirenz and tenofovir affect the PK of kanamycin? 
 
2.10.1 Objectives of the study  
The objectives of the present study are: 
1. To determine the plasma concentration of kanamycin using LC/MS. 
2. To determine the PK of kanamycin in patients with MDR-TB infection and in 
patients with MDR-TB co-infected with HIV; 
3. To determine if HIV infection influences the PK of kanamycin;  
4. To assess if kidney dysfunction affects the PK of kanamycin; and 
5. To find out if there is any interaction between ARVs and kanamycin and to what 
extent it influences the PK of kanamycin. 
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CHAPTER 3: METHODS 
 
3.1 Structure of the methods  
Chapter 3 gives a detailed description of the methods used in the study. The first 
section provides the structure of chapter three. The second section gives a brief 
description of the duration of the study and the study site. In the third section the 
study design is described. In the fourth and fifth sections criteria for including and 
excluding participants in the study are highlighted. The sixth section discusses the 
demographic, clinical and therapeutic characteristics of patients. 
 
The seventh section gives a detailed description of laboratory tests done, including 
where they were performed. The eighth section provides study procedures. The 
process of kanamycin administration and blood sampling are explained. The ninth 
section explains the processes of determining kanamycin plasma concentrations in 
detail. The chemicals used in the study and their sources are listed, while 
chromatographic and mass spectrometric conditions are also described and the 
preparation of kanamycin stock solution and calibration standard is explained. 
 
The tenth section provides the determination of the PK parameters of kanamycin, 
as well as the definition of these parameters. The eleventh section explains the 
determination of the number of patients and statistical methods used in the 
analysis of data. The final section presents ethical processes that were considered 
and followed. 
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3.2 Study site 
The study was conducted at Brewelskloof Hospital in Worcester, Western Cape 
Province, South Africa. This is one of the South African hospitals specialising in 
the treatment of MDR-TB. 
 
3.3 Study design 
The study was designed as a prospective, two-group, non-randomized PK study 
involving male and female HIV-positive and HIV-negative patients on treatment 
for MDR-TB. 
 
3.4 Inclusion criteria 
A patient was included in the study if he/she complied with all of the following: 
a. Signature of an informed written consent form for the blood samplings 
after he/she had been given a clear explanation of the aims, procedures, 
advantages and disadvantages of the study in his/her first language 
b. Informed consent for an HIV test 
c. On kanamycin treatment for at least two weeks  
d. Adult patients aged 18–65 years   
e. MDR-TB sensitive to second-line anti-TB drugs. 
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3.5 Exclusion criteria 
A patient was excluded from the study if one or more of the following criteria 
applied: 
a.  On the patient’s request 
b.  History of congestive cardiac failure 
c.  Uncontrolled hypertension 
d.  Ischemic heart disease 
e.  Pregnancy or breast feeding 
f.   Hypersensitivity to kanamycin 
g.  Older than 65 years 
i.    Haemoglobin less than 7g%. 
 
3.6 Demographic, clinical and therapeutic characteristics 
The demographic characteristics such as age, body weight, height and gender 
were recorded for every patient. Clinical and therapeutic characteristics such as 
viral load and CD4 counts were recorded for HIV-positive patients. In addition, 
kidney and liver function tests were determined for each patient after inclusion in 
the study. These characteristics were captured on a computer spreadsheet 
designed for the study. 
 
3.7 Laboratory tests 
The liver function, kidney function and haematology tests were done at PathCare 
laboratory (PathCare Park, Neels Bothma Street, N1 City, Goodwood, Cape 
Town, South Africa) in order to assess liver and kidney function and to determine 
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the haematological profile of the patients. HIV, viral load, CD4 counts and 
sputum microbiology tests were done by the National Health Laboratory Services. 
 
3.7.1 Liver function tests  
Liver function was evaluated using the Child-Pugh score. In calculating this score, 
clinical and biochemical measurements such as hepatic encephalopathy, ascites, 
total bilirubin, serum albumin and prothrombin time were graded based on 
standardised points.  
 
Table 3.1: Scoring system used for Child-Pugh classification 
Clinical and 
biochemical 
Measurements 
Points scored for increasing abnormality 
1 2 3 
Hepatic encephalopathy None 1 and 2 3 and 4 
Ascites Absent Mild Moderate 
Total bilrubin (mg/dl) <2.0 2.0-3.0 >3.0 
Serum albumin (g/dl) >3.5 2.8-3.5 <2.8 
Prothrombin time <4 or <1.7 4-6 or 1.7-2.3 >6 or >2.3 
Source: Trey et al. (1996) 
 
The individual points were added and then graded according to the severity of 
liver disease, as explained in the previous chapter. 
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3.7.2 Kidney function tests  
Kidney function was determined by calculating the GFR from serum creatinine 
using the MDRD formula: 
 
GFR (ml/min/1.73m
2
) = 175 x {[standardized SCr (µmol/L)/88.4]
-1.154
} x {age 
(years)
-0.203
} x (0.742 if female) x (1.210 if black). 
SCr= serum creatinine 
 
3.7.3 Haematological tests 
The full blood count was determined for each patient. However, our main interest 
was in the assessment of the CD4 cell count, which indicates the immuno-
competence level in HIV -positive patients. 
 
3.7.4 Sputum microbiological test 
The sensitivity test for MTB was identified in the sputum of patients for each 
second-line anti-TB drug before the start of the treatment. At Brewelskloof 
Hospital the second-line anti-TB drugs used were kanamycin, ofloxacin, 
pyrazinamide, ethionamide, ethambutol and terizidone. 
 
3.7.5 HIV test and determination of viral load and CD4 counts  
After individual pre- and post-test counselling regarding the HIV test, ELISA was 
conducted for every patient. Tests for viral load level and CD4 count were 
performed for HIV -positive patients. 
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3.8 Study procedures     
3.8.1 Blood sampling for kanamycin plasma concentrations 
On the study day, after an eight-hour overnight fast, patients received kanamycin 
at 7 a.m. All patients were allowed to have breakfast 30 minutes after drug 
administration. Blood samples were collected in appropriate tubes in the 
following order: 
i. Five (5) milliliters for liver and renal function tests 
ii. Five (5) milliliters for haematological and virological tests 
iii. Five (5) milliliters for assessment of kanamycin plasma concentrations.  
 
3.8.2 Kanamycin administration 
Patients received kanamycin injection intramuscularly at different doses (500, 
600, 660, 750 and 1000 mg) daily based on the patients’ body weight and renal 
function.  
 
3.9 Determination of kanamycin plasma concentrations  
Plasma levels of kanamycin were determined using LC-MS at Stellenbosch 
University, Cape Town, South Africa.  
 
3.9.1 Chemicals 
The following chemicals were used in the study: analytical-grade dimethyl 
sulfoxide (DMSO), acetonitrile, trichloroacetic acid, phosphoric acid and HPLC-
grade trifluroacetic acid (TFA). All of them were obtained from Sigma-Aldrich 
(Cape Town, South Africa). Kanamycin was supplied by Brewelskloof Hospital 
 
 
 
 
68 
 
and used as the working standard. 
 
3.9.2 Chromatographic and mass spectrometric conditions 
3.9.2.1 Column liquid chromatography 
The liquid chromatography was performed with the Waters 2695 HPLC system 
(Waters, Microsep Pty Ltd). The column utilised was a polar C18 liquid 
chromatography column, Waters Atlantis™ (5 µm, 2.1 mm x 100 mm) at ambient 
temperature. The mobile phase used was 0.1% TFA at a flow rate of 0.20 ml/min 
and an injection volume of 5 µl. 
 
3.9.2.2 Mass spectrometry setting 
The instrument used was a Waters API Quattro Micro triple quadrupole mass 
spectrometer with electrospray ionisation (Waters, Microsep Pty Ltd). The ion 
source and desolvation temperatures were held at 120°C and 400°C, respectively. 
The capillary voltage was 2.8 kV. The desolvation gas was at 1000 L/h and the 
cone gas was at 50 L/h. The instrument was operated at multiple reaction 
monitoring (MRM) mode. The MRM settings for kanamycin was 485>163 at 
collision energy of 25 eV, and cone voltage of 20 V.   Propranolol was used as 
internal standard and was monitored at an MRM of 260.3 > 183 at collision 
energy of 20eV and cone voltage of 18V. Waters Mass Lynx
TM
 software was used 
for data collection, integration and calibration. 
 
3.9.2.3 Kanamycin stock solution  
The stock solution of 1mg/ml was serially diluted with acetonitrile to obtain 
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working solutions with the concentrations 10, 5, 1, 0.5, 0.1 and 0.05 µg/ml. All 
these standards contained 10 ppm propranolol as internal standard. 
 
3.9.2.4 Preparation of calibration standards 
Kanamycin plasma calibration standards were prepared by spiking blank plasma 
with kanamycin working solution (with concentrations of 10, 5, 1, 0.5, 0.1 and 
0.05 µg/ml).  
 
3.9.2.5 Patient samples preparation 
To prepare the patients’ plasma samples for the LC-MS assay, trichloroacetic acid 
(30µl) was added to 50 µl plasma followed by 170 µl internal standard solution 
(10 ppm propanolol in water). The mixture was vortexed for 1 minute, followed 
by centrifugation at 6000 g for 5 minutes. The supernatant was injected onto the 
LC-MS. Blank plasma was spiked with 1 and 5 ppm of kanamycin in triplicate to 
determine the recoveries and repeatability. The relative standard deviation was 
better than 12%.   This relatively high standard deviation and relatively high limit 
of detection and quantification is due to the fact that kanamycin elutes just after 
the void volume of the column.  The use of a very polar C18 column is very 
important for this analysis  
 
3.10 Determination of pharmacokinetic parameters 
The plasma concentration-time profile for each patient was plotted manually. 
Kanamycin PK parameters were calculated based on the non-compartmental 
analysis (Mugabo, 2009) and expressed as median and range (lowest to highest) 
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as follows: 
 
3.10.1 The maximum concentration and the time to reach maximum 
concentration 
The maximum concentration (Cmax) and the time to reach the maximum 
concentration (Tmax) were obtained directly from the plasma concentration-time 
profile. 
 
3.10.2 The elimination rate constant 
The elimination rate constant (Ke) was determined from the terminal linear phase 
of the plasma concentration-time profile.  
 
Since natural log was used, the slope was calculated as  
Slope =  (ln y2 - ln y1 / x2-x1), 
Ke was obtained as – (slope) 
 
3.10.3 The absorption rate constant 
The absorption rate constant (Ka) was calculated by plotting the residual 
concentrations using the method of residuals and determining the slope from the 
straight line. Ka was then obtained from the slope of the straight line, which 
represents absorption phase. 
 
Ka is equal to – (slope) = –  (ln y2- ln y1/x2-x1) 
(Dipiro et al., 2010) 
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3.10.4 The half-life 
The half-life (t½) was calculated using the formula: t½ = 0.693/Ke. 
 
3.10.5 The area under the plasma concentration-time curve 
The area under the plasma concentration-time curve from zero to 24 hours  
(AUC0-24) was calculated by the trapezoidal method manually.  
 
The area under the plasma concentration-time curve from zero to infinity    
(AUC0-∞) was calculated using the following formula:  
AUC0-∞ = AUC0-24 + Cplast/Ke 
Where Cplast is the last measurable plasma concentration. 
 
3.10.6 The volume of distribution 
The following formula was used to determine the volume of distribution (Vd):  
Vd = Dose/ (AUC0-∞ x Ke). 
 
3.10.7 The total body clearance 
The total body clearance (Cltot) was calculated using the following formula: 
Cltot = Dose/AUC0-∞ 
 
3.10.8 The mean residence time 
The MRT was calculated as: MRT = AUMC∞/AUC∞ 
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Where AUMC∞ is the area under the momentum curve from zero to infinity and 
was calculated as: 
AUMC∞= AUMC+ (Clast / Ke
2
) + tlast x Clast/Ke 
AUMC=  tici + ti-1 x ci-1 
                        2 
Where Clast is the last measurable plasma concentration and tlast is the time of the 
last measurable concentration. 
 
3.11 Determination of the number of patients and statistical analysis of data 
3.11.1 Determination of the number of patients 
The number of patients to be included in the study was determined by using a 
two-sample t-test and comparing means to see if there is a possibility of detecting 
a difference between HIV-positive and HIV-negative patients. 
 
3.11.2 Statistical analysis of data 
Patients’ data collected during the study was organised by the researcher and 
coded onto data collection forms anonymously before being captured into 
computer files. Microsoft Excel was utilised for computer management of the 
data, which was reported as median and range. Analysis was done using SAS 
version 9.0. 
 
Basic statistics like mean, standard deviation, median and range were used to 
describe continuous and ordinal variables and frequency tables for nominal 
variables. When data was not normally distributed, the Wilcoxon Rank Sum test, 
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the non-parametric alternative to a paired t-test, was used and PK parameters were 
reported as median and range. The Kruskal-Wallis one-way analysis of variance 
was used in comparing more than two groups to see if they originate from the 
same population.  
 
Statistical significance was assumed at the p<0.01 level to avoid a type 1 error 
(false positive). 
 
3.12 Ethical considerations 
The study was approved by the University of the Western Cape ethics committee 
(Ethics certificate number: 07/6/12). It was conducted according to the declaration 
of Helsinki and ICH guidelines. Patients were provided with information sheets 
about the study, as mentioned above, and all information obtained during the 
study was treated as confidential. Permission to conduct the study was granted by 
the Provincial Department of Health and the medical superintendent of 
Brewelskloof Hospital. 
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CHAPTER 4: RESULTS 
 
4.1 Structure of the results 
Chapter 4 presents the results of the study. Tables and graphs are used 
appropriately to describe the findings. The first section provides the structure of 
chapter four. The second section describes the validation of LC-MS assay as a 
sensitive and specific method in the analysis of the plasma concentrations of 
kanamycin using graphs. The third section presents the demographic data in 
patients that participated in the study. Following this section are tables 
highlighting the virological and immunological profile in HIV-positive patients 
who participated in the study. Similarly, there are tables presenting renal function 
in HIV-positive and HIV-negative patients. 
 
The fourth section describes kanamycin plasma concentrations at different time 
intervals in both HIV-positive and HIV-negative patients. It also describes 
kanamycin PK parameters in both groups of patients. 
 
 
4.2 Kanamycin liquid chromatography-mass spectrometry analysis method 
validation 
Liquid chromatography coupled with mass spectrometry was used in the 
quantification of kanamycin plasma concentrations. This method was validated by 
determining linearity, recovery, precision and accuracy, low limit of detection, 
low limit of quantification, and specificity. 
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4.2.1 Calibration curve and linearity 
As indicated in Figure 4.1, the kanamycin calibration curve was constructed by 
plotting responses (y-axis) against corresponding concentrations (x-axis). The 
calibration curve was linear over ranges of -0.1–10 µg/ml-. The correlation co-
efficient (r
2
) was 0.97.  
 
Kanamycin concentration (µg/ml)
 
Fig 4.1: Kanamycin calibration curve 
 
4.2.2 Precision, recovery and accuracy 
The overall precision expressed as relative standard deviation (RSD%), was less 
than 12%. The accuracy, expressed in terms of recovery was 74 ± 9.1% and 111 ± 
6.2% for 1 µg/ml and 5 µg/ml, respectively. 
      
4.2.3 Lower limit of detection and quantification 
The lower limit of detection of kanamycin was 0.06 µg/ml. The lower limit of 
quantification of kanamycin in the plasma was found to be 0.15 µg/ml. 
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4.2.4 Specificity 
 
There were no interfering peaks from the plasma components with kanamycin 
peak, which was detected at a retention time of 2.65 minutes. Chromatograms 
showing the separation of kanamycin standard and kanamycin plasma extract 
(calibration standard) in addition to the blank plasma are shown in Figure 4.2. 
 
(A) Chromatogram of kanamycin standard drug 
 
 
 
 
 
(B) Chromatogram of kanamycin patient plasma 
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C ) Chromatogram of a blank plasma 
48
1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0
%
0
100
12.42
5.780.30
0.65
3.81
3.152.582.46
1.740.82
5.35
4.51
8.656.796.16
6.27
7.87
7.11
8.40
9.88
9.69
8.95 11.40
10.64
11.80
12.58
13.61
 
Figure 4.2: Kanamycin chromatograms: (A) Chromatogram of kanamycin 
standard drug; (B) Chromatogram of kanamycin in a patient’s plasma; (C) 
Chromatogram of a blank plasma 
 
4.3 Patients’ demographic data and characteristics 
Thirty-one black and coloured (mixed race) patients (17 males and 14 females) 
infected with MDR-TB participated in the study. Of these 31 patients, 13 (8 males 
and 5 females) were infected with HIV. The median (range) age and weight of 
patients were 32 (18–54) years and 53.0 (41.8–90.0) kg, respectively. 
 
4.3.1 Number of HIV-positive patients on antiretroviral treatment 
Of the 13 patients infected with HIV, only ten were on ARV therapy. The patients 
were taking the following ARVs: stavudine (30 mg/po/bd), lamivudine (150 
mg/po/bd) and efavirenz (600 mg/po/nocte). 
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Table 4.1: Immunological profile in HIV-infected patients 
CD4 count (range) cells/mm
3
 Number and gender 
<60 4 (2 males and 2 females) 
90–99 1 (1 male) 
100–299 3 (1 male and 2 females) 
300–399 3 (3 males) 
400–599 2 (1 male and 1 female) 
 
From Table 4.1, five patients infected with HIV had a CD4 count of <100 
cells/mm
3
. Eight HIV-positive patients had a CD4 count of >100 cells/mm
3
.  
 
Table 4.2: Virological profile in HIV-infected patients 
Viral load (range) copies/ml Number and gender 
<40 10 (7 males and 3 females) 
5,000–1,000,000 3 (1 male and 2 females) 
 
Table 4.2 shows viral load in all the HIV-positive patients who participated in the 
study. The viral load varied among HIV-positive patients. Ten patients had a viral 
load of less than 40 copies/ml and three patients had a viral load of 5,000–
1,000,000 copies/ml. 
 
  
 
 
 
 
79 
 
Table 4.3: Renal function in HIV -positive and in HIV -negative patients 
GFR (ml/min/1.73 m
2
) Number of patients 
Normal (>90) 5 HIV-positive and 15 HIV-negative 
Mild (60–89) 8 HIV-positive and 3 HIV-negative 
Moderate (40–59) 2 HIV-positive  
 
Table 4.3 presents renal function in HIV-positive and HIV-negative patients that 
participated in the study. Eleven patients in total had mild renal function and only 
two patients had moderate renal function. The median value for the GFR in HIV-
positive patients was 80 (44–88) ml/min. Similarly, the median value for GFR in 
HIV-negative patients was 88 (84–89) ml/min. 
 
4.4 Kanamycin plasma concentrations and pharmacokinetic parameters  
4.4.1 Kanamycin plasma concentrations  
Kanamycin plasma concentrations at different time intervals after kanamycin 
intramuscular administration over a 24-hour period are shown in the plasma 
concentration-time graphs in Tables 4.4–4.5. 
 
4.4.1.1 Kanamycin plasma concentration in HIV-positive and HIV-negative 
patients 
Tables 4.4–4.5 illustrate kanamycin plasma concentrations in HIV-positive and 
HIV-negative patients. 
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Table 4.4: Kanamycin plasma concentration-time profile in HIV-positive 
patients 
 
 
BDL = below detectable level (0.05µg/ml) 
N/A= not applicable. 
 
As indicated in Table 4.4, kanamycin plasma concentrations are below detectable 
level at base line (0hr), 0.5hr and 24hrs. Peak plasma concentration is at 1hr. 
 
 
Patient Baselin
e (0 hr) 
(µg/ml) 
                     Time (hours) after kanamycin administration 
 0.5hr 
(µg/ml) 
1hr 
(µg/ml) 
2hrs 
(µg/ml) 
4hrs 
(µg/ml) 
8hrs 
(µg/ml) 
24hrs 
(µg/ml) 
1 BDL BDL 14.47 12.95 9.98 BDL BDL 
2 BDL BDL 21.67 17.64 13.06 8.13 BDL 
3 BDL BDL 14.35 12.95 9.42 8.18 BDL 
4 BDL BDL BDL 12.71 8.06 2.70 0.66 
5 BDL BDL 5.15 8.40 5.22 2.85 0.75 
6 7.80 BDL 21.67 20.99 14.95 13.70 9.29 
7 BDL BDL 19.36 9.82 11.11 8.37 BDL 
8 BDL BDL 16.15 18.19 13.77 9.85 BDL 
9 7.46 BDL 19.77 19.81 13.02 9.35 BDL 
10 BDL BDL 27.63 16.76 9.23 3.34 5.82 
11 BDL 12.23 11.22 7.42 5.53 2.61 BDL 
Median N/A N/A 16.15 12.95 9.98 8.13 N/A 
Range N/A N/A 5.15-27.63 7.42-20.99 5.22-14.95 2.61-13.70 N/A 
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Table 4.5: Kanamycin plasma concentration-time profile in HIV-negative 
patients 
 
 
From table 4.5, it is observed that kanamycin plasma concentrations are below 
detectable level at baseline, 0.5hr and 24hrs. Peak plasma concentration is at 1hr. 
Patient Baseline 
(0hr) 
(µg/ml) 
Time (hours) after kanamycin administration 
 0.5hr 
(µg/ml) 
1hr 
(µg/ml) 
2hrs 
(µg/ml) 
4hrs 
(µg/ml) 
8hrs 
(µg/ml) 
24hrs 
(µg/ml) 
 
12 BDL BDL 14.19 10.26 9.44 BDL BDL 
13 BDL BDL 25.26 22.57 15.28 8.94 BDL 
14 BDL BDL 18.18 16.36 12.75 9.05 BDL 
15 BDL BDL 23.55 13.38 9.82 7.92 BDL 
16 BDL BDL 18.64 18.34 10.86 7.56 BDL 
17 BDL 13.32 11.87 6.38 2.85 0.77 1.72 
18 BDL BDL 7.21 15.82 9.82 7.60 7.26 
19 BDL BDL 17.94 17.33 11.59 8.87 BDL 
20 BDL BDL 14.16 BDL 10.97 8.14 8.39 
21 BDL BDL 24.19 23.87 12.69 9.05 BDL 
22 BDL BDL 24.11 17.85 11.76 BDL BDL 
23 BDL BDL 19.06 21.71 10.33 8.30 BDL 
24 BDL BDL 17.90 18.60 12.16 9.59 BDL 
25 BDL BDL 14.88 8.16 5.54 2.03 BDL 
Media
n 
N/A N/A 18.06 16.85 10.92 8.03 N/A 
Range N/A N/A 7.21-
25.26 
6.38-
23.87 
2.85-
15.28 
0.77-9.59 N/A 
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The median plasma concentration-time profile of kanamycin in HIV-positive and 
HIV-negative patients is shown in Figure 4.3. 
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Figure 4.3: Kanamycin median plasma concentration-time profile in HIV-
positive and HIV-negative patients 
 
From Figure 4.3, it can be observed that the plasma concentration profile of 
kanamycin in the 11 HIV-positive and 14 HIV-negative patients are similar. There 
is no significant difference (p =0.43) at all sampling times.  
 
4.4.1.2 Kanamycin plasma concentrations in additional patients 
Plasma concentrations in the additional six patients that were introduced into the 
study are shown in Table 4.6.
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Table 4.6: Kanamycin plasma concentration-time profile in additional patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.6 presents kanamycin plasma concentrations at different time intervals in the additional patients. These concentrations were not added to 
concentrations in the previous patients because of the different blood  sampling times.
     Time after kanamycin administration 
 Baseline 
(0hr) 
(µg/ml) 
15mins 
(µg/ml) 
25mins 
(µg/ml) 
35mins 
(µg/ml) 
45mins 
(µg/ml) 
55mins 
(µg/ml) 
65mins 
(µg/ml) 
90mins 
(µg/ml) 
2hrs 
(µg/ml) 
4hrs 
(µg/ml) 
8hrs 
(µg/ml) 
16hrs 
(µg/ml) 
24hrs 
(µg/ml) 
26 BDL 8.27 5.53 13.69 11.13 12.71 9.08 9.30 9.83 6.90 3.03 1.01 BDL 
27 BDL 1.71 7.47 13.23 23.04 17.48 22.12 21.57 20.48 7.54 1.20 BDL BDL 
28 BDL 3.01 5.25 10.16 5.22 6.57 6.67 5.95 10.57 5.55 0.88 BDL BDL 
29 BDL 3.07 6.20 6.90 9.78 10.83 12.08 10.38 9.91 5.06 BDL BDL BDL 
30 BDL 1.73 6.79 BDL 10.51 15.71 15.58 9.42 7.41 3.58 BDL BDL BDL 
31 BDL 0.20 0.81 1.24 1.84 3.73 6.73 5.46 5.07 3.03 0.65 BDL BDL 
Median BDL 2.37 5.87 8.53 10.15 11.77 10.58 9.36 9.87 5.31 1.04 BDL BDL 
Range BDL 0.20-
8.27 
0.81-
7.47 
1.24-
13.69 
1.84-
23.04 
3.73-
17.48 
6.73-
22.12 
5.46-
21.57 
5.07-
20.48 
3.03-
7.54 
0.65-
3.03 
N/A N/A 
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As indicated in Table 4.6, at baseline (before kanamycin administration), plasma concentrations were below 
detectable levels (0.05 µg/ml). This could be as a result of an insufficient amount of kanamycin remaining in 
the body 24 hours after dosing that could be detected at baseline. Also, plasma concentration levels were not 
detected within 16 and 24 hours in most patients. Plasma concentration levels were detected last at 16hrs for 
patient 26. Patient 26 had a moderate renal impairment of 51ml/min and this resulted in the lengthening of 
the residence time of kanamycin. 
 
4.4.2 Kanamycin pharmacokinetic parameters 
Tables 4.7, 4.8 and 4.9 demonstrate kanamycin PK parameters in HIV-positive, HIV-negative and additional 
patients, respectively. Patients were on MDR-TB treatment for two weeks.  
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Table 4.7: Kanamycin pharmacokinetic parameters in HIV-positive patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Ke 
(hr-1) 
 
Dose 
(mg) 
T1/2 
(hrs) 
AUC(0-24)  
µg/ml.hr 
AUC(0-∞)  
µg/ml.hr 
Cmax  
(µg/ml) 
Tmax 
(hrs) 
Ka 
(hr-1) 
AbsorptionT1/2 
(hrs) 
Vd (L) 
Cltot 
(L/hr) 
MRT 
(hrs) 
1 0.11 1000 6.30 60.22 150.95 14.47 1.00 N/A N/A 60.22 6.62 7.92 
2 0.18 750 3.85 163.20 208.37 21.67 1.00 N/A N/A 20.00 3.60 2.99 
3 0.079 1000 8.77 140.25 243.79 14.35 1.00 N/A N/A 51.92 4.10 8.80 
4 0.27 1000 2.57 75.53 77.97 12.71 2.00 N/A N/A 47.50 12.83 1.11 
5 0.16 1000 4.33 66.63 71.32 8.40 2.00 0.19 3.65 87.63 14.02 2.02 
6 0.063 750 11.00 305.86 453.32 21.27 1.00 0.16 4.33 26.26 1.65 12.96 
7 0.19 1000 3.65 146.28 190.33 19.36 1.00 0.44 1.58 27.65 5.25 3.12 
8 0.13 1000 5.33 179.21 254.98 18.19 2.00 0.85 0.82 30.17 3.92 4.69 
9 0.22 750 3.15 178.97 221.47 19.81 2.00 0.90 0.77 15.39 3.39 2.39 
10 0.33 750 2.10 153.52 171.16 27.63 1.00 0.33 2.1 13.28 4.38 2.87 
11 0.22 750 3.15 68.35 80.21 12.23 0.50 0.42 1.65 42.50 9.35 1.86 
Median 0.18 1000 3.85 146.28 190.33 18.19 1.00 0.19 0.82 30.17 4.38 2.99 
Range 0.063-
0.33 
750-
1000 
2.10-
11.00 
60.22-305.86 71.32-453.32 8.40-27.63 0.50-
2.00 
0.16-
0.90 
0.77-4.33 13.28-
87.63 
1.65- 
14.02 
1.11-
12.96 
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Table 4.8: Pharmacokinetic parameters in HIV -negative patients 
 
 
Patient 
 
 
Ke 
 
 
T1/2 
 
 
 
Dose 
(mg)  
AUC(0-24)  
µg/ml.hr 
AUC(0-∞)  
µg/ml.hr 
Cmax 
(µg/ml) 
Tmax  
(hrs) 
Ka (hr
-1
) 
 
 
Absorption T1/2 
(hrs) Vd (L) 
 
Cltot 
MRT (hrs) 
(hr
-1
) (hrs)   
 
(L/hr) 
    
  
  
12 0.34 2.04 750 54.36 82.12 14.19 1 N/A N/A 26.86 9.13 2.43 
13 0.15 4.62 750 188.04 247.64 25.26 1 N/A N/A 20.19 3.03 3.58 
14 0.11 6.3 750 166.93 249.2 18.18 1 N/A N/A 27.36 3.01 5.68 
15 0.29 2.39 750 146.4 173.71 23.55 1 N/A N/A 14.89 4.32 1.87 
16 0.12 5.78 750 149.67 212.67 18.64 1 N/A N/A 29.39 3.53 4.88 
17 0.35 1.98 750 55.15 60.06 13.32 0.5 N/A N/A 35.68 12.49 2.21 
18 0.12 5.78 1000 192.68 253.18 15.82 2 0.13 5.33 32.91 3.95 4.87 
19 0.096 7.22 1000 162.93 255.33 17.94 1 N/A N/A 40.8 3.92 6.7 
20 0.081 8.56 1000 192.05 295.63 14.16 1 N/A N/A 41.76 3.38 12.76 
21 0.14 4.95 1000 182.52 247.16 24.19 1 N/A N/A 28.9 4.05 4.01 
22 0.23 3.01 1000 80.14 131.27 24.11 1 N/A N/A 33.12 7.62 3.34 
23 0.12 5.78 1000 160.86 230.03 21.71 2 0.26 2.67 36.23 4.35 4.95 
24 0.084 8.25 1000 173.61 287.78 18.6 2 0.94 0.74 41.37 3.47 7.93 
25 0.33 2.1 1000 60.32 66.47 14.88 1 N/A N/A 45.59 15.04 1.13 
Median 0.13 5.37 1000 161.9 236.6 18.39 1 N/A N/A 33.02 4 4.44 
Range 0.081-0.35 1.98-8.56 750-1000 54.36-192.68 60.06-295.63 13.32-25.26 0.50-2.00 N/A N/A 14.89-45.59 3.01-15.04 1.13-12.76 
Result from 
published 
studies 
0.29-0.30 4 500-2000 N/A N/A 20.00-35.00 1.00-2.00 N/A N/A 17.00-23.00 5.00-6.00 N/A 
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Ranges of pharmacokinetic parameters of kanamycin in HIV -negative patients from previous published 
studies are shown in the last row of Table 4.8. 
 
As indicated in table 4.7 and 4.8, Ka and absorption t1/2 were not calculated for patients in whom there was 
no absorption phase of kanamycin. 
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Table 4.9: Pharmacokinetic parameters in additional patients 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Ke 
(hr-1) 
T1/2 
(hrs) 
 
Dose 
(mg) 
AUC(0-24)  
µg/ml.hr 
AUC(0-∞)  
µg/ml.hr 
Cmax  
(µg/ml) 
Tmax 
(hrs) 
Ka  
(hr-1) 
AbsorptionT1/2 
(hrs) 
Vd (L) 
Cltot 
(L/hr) 
MRT 
(hrs) 
26 0.16 4.33 1000 71.52 77.75 13.69 0.58 0.35 1.98 80.39 12.86 1.78 
27 0.44 1.58 660 82.12 84.85 23.04 0.75 1.55 0.45 17.68 7.78 0.33 
28 0.27 2.57 1000 44.58 47.84 10.57 2.00 1.95 0.36 77.42 20.90 0.79 
29 0.25 2.77 1000 41.72 61.96 12.08 1.08 3.84 0.18 64.56 16.14 2.61 
30 0.32 2.17 660 34.50 45.69 15.71 0.92 2.29 0.30 45.14 14.45 1.74 
31 0.19 3.65 1000 25.07 28.49 6.73 1.08 1.89 0.37 184.74 35.10 1.60 
Median 0.26 2.67 1000 43.15 54.90 12.89 1.00 1.92 0.37 70.99 15.30 1.67 
Range 0.16-
0.44 
1.58-
4.33 
660-
1000 
25.07-82.12 28.49-84.85 6.73-23.04 0.58-
2.00 
0.35- 
3.84 
0.18- 
1.98 
17.68-
184.74 
7.78- 
35.10 
0.33-
2.61 
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In table 4.10, the GFR and PK parameters in HIV -positive and HIV -negative patients are 
compared using the Wilcoxon rank sum test to see if there is any statistically significant 
difference. 
 
Table 4.10: p values for Wilcoxon non-parametric test 
Glomerular filtration rate and 
Pharmacokinetic parameters  
p value 
GFR 0.013 
Ke 1.00 
T1/2 1.00 
AUC0-24 0.61 
AUC0-∞ 0.43 
Cmax 0.47 
Tmax 0.63 
Vd 0.77 
Cltot 0.51 
MRT 0.50 
 
As indicated in table 4.10, there is no significant difference in the PK parameters of 
kanamycin in HIV positive and HIV negative patients except for the GFR which has a p 
value of 0.013. 
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CHAPTER FIVE: DISCUSSION 
 
5.1 Structure of the discussion 
Chapter 5 discusses the study design, study procedures, the determination of kanamycin 
plasma concentrations, the statistical methods and results obtained from the study. It consists 
of 16 sections. 
 
The first section presents the structure of chapter five. The second section discusses the 
demographic characteristics of patients who participated in the study. The power calculation 
used to determine the number of patients needed for the PK study is also discussed. The third 
section discusses the procedures used in the study. In this section, the blood sampling of 
patients is explained. 
 
The fourth section discusses the LC-MS method of analysis. In this section LC/MS is 
compared to previously used methods to determine kanamycin plasma concentrations. The 
fifth and sixth section explains kidney and liver function tests in HIV -positive and in HIV -
negative patients.  
 
The seventh section explains the virological and immunological profile in HIV-positive 
patients. The eighth section discusses the statistical methods used to analyse kanamycin PK 
parameters. In the ninth, tenth and eleventh sections, research questions in the study are 
extensively answered based on the results given in the previous chapter. 
 
The twelfth section deals with abnormal PK parameters in HIV-negative patients compared to 
previously published studies. The thirteenth section discusses kanamycin plasma PK in the 
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six additional patients. The PK parameters of kanamycin in previously published studies are 
discussed in the fourteenth section.  
 
The fifteenth section discusses the therapeutic implications of the study. It presents the two 
PK parameters associated with the clinical efficacy of kanamycin in patients and explains 
their significance. Finally, the sixteenth section explains the limitations of the study. 
 
5.2 Study design 
5.2.1 Demographic characteristics 
The 31 (17 males and 14 females) patients who participated in the study were sufficient to 
describe the PK of kanamycin in patients with MDR-TB. The number of patients in HIV-
positive and HIV-negative groups was sufficient to give a power of about 80% in detecting a 
statistical significant difference in the means of about 1.2 standard deviations based on our 
power calculations. Also, the number of patients who participated in previously published 
studies was similar to the number of patients in our study. 
 
In the study on serum PK of anti-mycobacterial drugs in HIV -negative patients with MDR-
TB during therapy, 13 patients participated in the study (Yew et al., 1999). Furthermore, a 
sample size of ten patients was seen in studies of kanamycin in healthy volunteers (Cronk and 
Naumann, 1959; Doluiso et al., 1973; Clarke et al., 1974). Twelve patients participated in a 
study on the comparative PK of BB-K8 and kanamycin humans (Cabana and Taggart, 1973). 
Based on the number of patients in previous studies, our sample size of 31 was sufficient to 
describe the PK of kanamycin in patients with MDR-TB and in those with MDR-TB co-
infected with HIV. 
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Patients’ age ranged from 18 to 54 years, which is an active age group and is within the 
inclusion criteria. From the body mass index (BMI), most patients had normal body weight. 
Sixteen patients had normal body weight (18.5–24.9 BMI), 11 patients were underweight 
(<18.5 BMI) and four patients were overweight (25.0–29.9 BMI). 
 
5.3 Study procedures 
5.3.1 Blood sampling for kanamycin plasma concentrations 
The stability of plasma samples was maintained by storing samples at -80˚C until LC-MS 
analysis.  
 
As indicated in Table 4.4, patient 6 had a concentration-time profile starting at 0 hr and 
ending at 24 hrs. The reason for this is because patient 6 had a moderate renal impairment of 
44ml/min, which contributed to the reduced Cltot of 1.65 L/hr and the long t1/2 of 11.00 hrs. 
Patient 10 and 4 also had concentration values ending at 24hrs, although there were no 
detectable plasma concentrations at 0 hour. Patients 10 and 4 both had normal renal function 
of 90ml/min. 
 
From Tables 4.4 and 4.5, plasma concentrations were not detected in most patients at baseline 
(0 hour). This suggests that there was insufficient amount of kanamycin remaining in the 
body 15 to 20 hours after kanamycin administration that could be detected at baseline (24 
hours after dosing). In addition, there were no plasma concentration values in most patients 
within 30 minutes after kanamycin intramuscular administration. These concentrations are 
below detectable level.  
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An additional kanamycin plasma concentration of six patients were analysed at time intervals 
of 15, 25, 35, 45, 55, 65 and 90 minutes and 2, 4, 8, 16 and 24 hours; this was in addition to 
our previous 25 patients. This was done in order to be able to see if we could detect the Cmax 
and Tmax of kanamycin between 0.25 and 1 hour and to find out if it differs from our previous 
patients. 
 
5.4 The Liquid chromatography-mass spectrometry method of analysis 
The LC-MS method is a proven method and has been widely used in the quantification of 
anti-TB drugs (Peng et al., 1977; Maitra et al., 1979; Niessen, 1998; Mugabo et al., 2009). 
The plasma levels of kanamycin were determined using LC-MS method and analysis was 
conducted according to scientific standards. 
 
5.4.1 Validation of liquid chromatography-mass spectrometry 
To validate the assay, linearity, lowest limit of detection, lowest limit of quantification, 
specificity, precision, recovery and accuracy were determined in the previous chapter. All 
chemicals used were prepared and standardised regularly. Chemicals were obtained from a 
reputable source (Sigma-Aldrich, Cape Town). Separation of kanamycin was achieved at a 
retention time of 1.50 minutes with a high recovery percentage of 92.5%. 
 
In summary, previously published studies have used microbiological and fluoroimmuno 
assay in the quantification of kanamycin (Cronk and Naumann, 1959; Doluiso et al., 1973; 
Clarke et al., 1974; Yew et al., 1999). However, our validation results demonstrate that the 
LC-MS analysis method is highly successful and accurate in the detection and quantification 
of kanamycin in plasma. 
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5.5 Kidney function tests 
Kidney function was assessed by evaluating GFR calculated from the MDRD formula. The 
MDRD formula was preferred in evaluating GFR because it allows for adjustment for body 
surface area. Normal renal function is equal or greater than 90 ml/min. Impaired renal 
function includes mild (60–89 ml/min), moderate (40–59 ml/min) and severe renal 
impairment (<15 ml/min). 
 
Eleven patients (eight HIV-positive and three HIV-negative) had mild renal impairment and 
two HIV-positive patients had moderate renal impairment. The median GFR for patients with 
normal GFR was >90 ml/min, for patients with mild renal impairment it was 84 ml/min and 
for those with moderate renal impairment it was 48 ml/min. The median GFR for HIV-
positive patients with a CD4 count less than 100 cells/mm
3
 and a CD4 count greater than 100 
cells/mm
3
 was 81 and 88 ml/min respectively. This indicates that there was no significant 
change in the GFR in HIV positive patients according to the level of HIV infection. 
 
5.6 Liver function tests 
Liver function was evaluated using the Child-Pugh score. The score was normal (< 10) in all 
patients.  
 
5.7 Virological and immunological profile 
Viral load and CD4 count were performed by an accredited laboratory (National Health 
Laboratory Services) in order to determine the immune competence of HIV-positive patients 
in the study. There was an unequal balance of CD4 count and viral load among HIV-positive 
patients. Five patients had a CD4 count of less than 100 cells/mm
3
 and eight patients had 
CD4 counts greater than 100 cells/mm
3
.  
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As indicated in Table 4.2, ten HIV-positive patients had a viral load of <40 copies/ml and the 
remaining three had a viral load of 5,000–1,000,000. The reason for this variation of viral 
load in HIV-positive patients is that the ten patients were on ARV therapy and the other three 
were not. 
 
5.8 Statistical analysis of Pharmacokinetic parameters 
PK parameters were analysed using the Wilcoxon Rank Sum test, because PK data points 
were not normally distributed. The Wilcoxon Rank Sum test was used because we had one 
categorical variable (Pos) with two variables (HIV-positive and HIV-negative groups) and 
one nominal variable (Ke, Cmax, Vd, Cltot, MRT, AUC0-24, AUC0-∞ and t1/2, respectively).  
 
The median and ranges were used to express the PK parameters because of the skewed 
distribution of PK data points. These were used because they are not generally affected by 
extreme values or outliers and also useful when data are not normally distributed.  
 
The Kruskal-Wallis one-way analysis of variance is a non-parametric method and its 
equivalent is the one-way analysis of variance (ANOVA). The Kruskal-Wallis test was used 
to correlate the GFR values and PK parameters to see if there was a difference in the HIV 
positive and HIV negative groups of patients as a result of renal dysfunction.  
 
A p value of 0.43 suggests that there was no statistically significant difference in the PK 
parameters between HIV-positive and HIV-negative patients, and on this basis the null 
hypothesis was accepted in favour of the alternate hypothesis. 
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5.9 Could HIV infection influence the pharmacokinetics of kanamycin in patients 
infected with multi-drug resistant tuberculosis? 
The rate and extent of absorption of kanamycin as represented by the Cmax and AUC0-24 was 
similar in both HIV -positive and HIV -negative patients as indicated in Table 4.7 and 4.8. 
HIV positive patients were not severely affected by HIV (Table 4.1 and 4.2). Many HIV 
positive patients had good immunological and virological profile since eight out of thirteen 
patients had a CD4 count greater than 100 cells/mm
3
 and ten had viral load less than 40 
copies/ml. Furthermore, none of our patients had gastrointestinal diseases such as gastro-
enteritis, diarrhoea or vomiting that could have influenced the absorption rate of kanamycin 
in HIV -positive and HIV -negative patients (Arbex et al., 2010). Also, there were no 
observable side effects of antiretroviral drugs or MDR-TB drugs that could have affected the 
absorption of kanamycin in the patients. For example, diarrhoea is the major side effect of 
protease inhibitors that could reduce the bioavailability of kanamycin. Similarly, 
ethionamide, one of the MDR-TB drugs produces severe gastrointestinal effects that could 
affect the PK of kanamycin (Weyer, 2005). 
 
In addition, patients 1 and 3 had a low CD4 count of 17 and 20 cells/mm
3
, respectively, 
which might have contributed to the low Cmax of 14.47 and 14.35 µg/ml (Table 4.7), 
respectively. Some studies have suggested that there is altered absorption of anti-
mycobacterial drugs in patients with advanced HIV infection and with a history of low CD4 
counts (Patel et al., 1995; Berning et al., 2003; Gurumurthy et al., 2004). 
 
A  reduction in the extent of distribution of kanamycin in patients 9 and 10 with CD4 count 
of 382 and 336 cells/mm
3
 and represented by a Vd of 13.28 and 15.39 L, respectively, might 
be associated with the short t1/2 of 2.10 and 3.15 hours, respectively, that was observed. The 
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t1/2 of a drug is a PK parameter dependent on both Vd and CLtot and is a reflection of the 
extent of the distribution or elimination of a drug (Mehzar, 2004). Similarly, an increase in 
the Vd (60.22, 51.92, 26.26 and 30.17 L) of kanamycin in patients 1, 3, 6 and 8 resulted in the 
lengthening of the t1/2 of 6.30, 8.77, 11.00 and 5.33, respectively. 
 
The median and range for the Ka, Ke, t1/2, AUC0-24, AUC0-∞, Cmax, Tmax, Vd, Cltot and MRT of 
kanamycin in HIV -positive patients were 0.52 (0.16-0.90) hr
-1
, 0.18 (0.063-0.33) hr
-1
, 3.85 
(2.10-11.00) hrs, 146.28 (60.22-305.86) µg/ml.hr, 190.33 (71.32-453.32) µg/ml.hr, 18.19 
(8.40-27.63) µg/ml, 1.00 (0.50-2.00) hrs, 30.17 (13.28-87.63) L, 4.38 (1.65-14.02) L/hr and 
2.94 (1.11-12.96) hrs, respectively. There was no significant difference (p=0.43) in the PK 
parameters of kanamycin in HIV -positive patients when compared to the median PK 
parameters in HIV -negative patients. 
 
5.10 To what extent do changes in kidney function influence the pharmacokinetics of 
kanamycin? 
There was some apparent significant difference (p=0.013) in the renal function between the 
HIV positive and HIV negative patients. However, there was no significant difference 
(p=0.31) when we correlated the GFR values and the PK parameters in the two groups of 
patients to see if changes in the renal function affected the PK of kanamycin. HIV could be 
responsible for the significant difference in the renal function between HIV -positive and 
HIV -negative patients. A decline in renal function and low CD4 count are associated with 
HIV-related nephropathy, due to HIV infecting the renal cells directly (Gerntholz et al., 2006; 
Jeremy et al., 2008; Roe et al., 2008). Also, as indicated in Table 4.3, we had more patients 
with impaired renal function in the HIV -positive group than in the HIV -negative group and 
this could have contributed to the statistical difference. This result is consistent with a study 
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done in South African patients, reporting that HIV-related nephropathy is exhibited in HIV 
positive patients at any stage of HIV infection and is characterised with varying degrees of 
GFR (Gerntholz et al., 2006). 
 
Furthermore, individual change in PK parameters due to renal dysfunction was observed. 
Patient 6 had a moderate renal impairment of 44 ml/min. The decrease in GFR was associated 
with a decrease in Cltot (1.65 L/hr) and the result is an increase in the AUC0-24 (305.86 
µg/ml.hr) and Cmax (21.27 µg/ml) of kanamycin, as observed in this patient. This could be 
because kanamycin is primarily eliminated by the kidneys, and therefore its clearance can be 
prolonged in patients with renal impairment (Holdiness, 1984; Budha et al., 2008; Arbex et 
al., 2010).  
 
In addition, in Table 4.7, the other HIV-infected patients (patients 5 and 11) with mild renal 
impairment (64 and 85 ml/min respectively) and a CD4 count of (98 and 102) cells/mm
3
 had 
a significant increase in the clearance (14.02 and 9.35 L/hr) of kanamycin when compared to 
the other HIV -positive patients. This suggests that there was no relationship between mild 
renal impairment and the immunological profile in HIV positive patients 
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5.11 Do lamivudine, stavudine and efavirenz affect the pharmacokinetics of kanamycin? 
Kanamycin was administered with other MDR-TB drugs to all patients. Some of the HIV 
positive patients were also given lamivudine, stavudine and efavirenz.  None of these drugs 
can affect the metabolism, distribution and renal elimination of kanamycin.  
 
5.12 Abnormal pharmacokinetic parameters in HIV-negative patients 
Kanamycin exhibits low protein binding (approximately 10%) and therefore there should be a 
high Vd, because distribution is limited to extravascular tissues (Pechere and Dugal, 1979; 
Arbex et al., 2010).  Patients 14, 16, 18, 19, 20 and 24 had an increase in t1/2 of 6.30, 5.78, 
5.78, 7.22, 8.56 and 8.25 hours, respectively. The increase in t1/2 was as a result of the 
increase in the Vd of 27.36, 29.39, 32.91, 40.80, 41.76 and 41.37 L. This is consistent with 
the literature that kanamycin is highly distributed within extravascular tissues (Budha et al., 
2008). Similarly, a reduction in the Cltot of kanamycin of 3.01, 3.53, 3.95, 3.92, 3.38 and 3.47 
L/hr could have resulted in the lengthened t1/2 of kanamycin in these patients. 
 
In addition, the reduction in the rate and extent of absorption as represented by the low Cmax 
of 14.19, 13.32 and 14.88 µg/ml and low AUC0-24 of 54.36, 55.15 and 60.32 µg/ml.hr in 
patients 12, 17 and 25, respectively, could be as a result of the rapid clearance of 9.13, 12.49 
and 15.04 L/hr of kanamycin, respectively. The rapid elimination of kanamycin in these 
patients resulted in a short t1/2 of 2.04, 1.98 and 2.10 hours, respectively. It is difficult to 
explain the rapid clearance of kanamycin in these patients because they had normal renal 
function, were not suffering from any other disease, no drug–drug interactions were observed 
and they were all HIV-negative. 
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The median and range for the Ke, t1/2, AUC0-24, Cmax, Vd, MRT and CLtot of kanamycin in HIV 
-negative patients were 0.13 (0.081-0.35) hr
-1
, 5.37 (1.98–8.56) hours, 161.90 (54.36–192.68) 
µg/ml.hr, 18.39 (13.32–25.26) µg/ml, 33.02 (14.89–45.59) L, 4.44 (1.13–12.76) hours, 4.00 
(3.01–15.04) L/hr. When compared to previously published studies (Cronk and Naumann, 
1959; Cabana and Taggart, 1973; Clarke et al., 1974; Doluiso et al., 1973), there was a 
reduction in the rate and extent of absorption in HIV-negative patients. The t1/2 and MRT of 
kanamycin were lengthened in HIV-negative patients. The Vd was also increased. Ke and Cltot 
were decreased. The increase in the extent of distribution, the decrease in the elimination rate 
constant and the decrease in the clearance of kanamycin could be responsible for the 
lengthened time kanamycin molecules resided in HIV-negative patients. 
 
5.13 Additional patients’ results 
In addition to seeing clearly what is happening between the time intervals of 0.25 and 1 hour 
in the description of kanamycin PK parameters, blood samples were also collected at 
different time intervals because we were testing for ethionamide, which has a Tmax around 1 
hour. 
 
Kanamycin PK was determined in the six additional patients at the following time intervals: 
baseline (before kanamycin administration), 15, 25, 35, 45, 55, 65, 90 minutes and 2, 4, 8, 16 
and 24 hours after kanamycin administration, respectively. The PK parameters are expressed 
as median and range. Cmax, Tmax and AUC0-24 were 12.89 (6.73-23.04) µg/ml, 1.00 (0.58–
2.00) hours, and 43.15 (25.07–82.12) µg/ml.hr, respectively. MRT and t1/2 were 1.67 (0.33–
2.61) hours and 2.67 (1.58–4.33) hours, respectively. Vd and Cltot were 70.99 (17.68–184.74) 
L/hr and 15.30 (7.78–35.10) L, respectively. There was similarity in the PK parameters of 
kanamycin when compared to HIV -negative patients in the study. Kanamycin was not 
 
 
 
 
101 
 
adequately absorbed in the patients as represented by the low Cmax and AUC0-24. Kanamycin 
was highly eliminated as indicated by the high Ke and Cltot and this resulted in the short t1/2 
and MRT. 
 
5.14 Pharmacokinetic data of kanamycin from published studies 
There is not enough data from previous studies on the PK of kanamycin in patients with 
MDR-TB and in those with MDR-TB co-infection with HIV. Three studies have described 
the PK of kanamycin in healthy volunteers (Cronk and Nauman, 1959; Cabana and Taggart, 
1973; Doluiso et al., 1973) and only one described the PK of kanamycin in HIV -negative 
patients infected with MDR-TB (Yew et al., 1999) using immuno-assay methods. The ranges 
for some PK parameters from previous studies are as follows: Cmax of 20–35 µg/ml, Tmax of 
1–2 hours, Ke of 0.29–0.30 hr
-1
, t1/2 of 2–4 hours, Cltot of 5–6 L/hr and Vd of 17–-23 L. 
 
When comparing these results to PK parameters of HIV -negative patients in the study, the 
median Cmax (18.39 µg/ml) was lower in this study, Tmax (1hr) was similar, Ke (0.13hr
-1
) was 
lower, t1/2 (5.37hrs) was longer, Cltot (4.00L/hr) was lower and Vd (33.02L) was higher. 
 
 
5.15 Therapeutic implications 
The two common PK parameters associated with the clinical efficacy of aminoglycosides are 
Cmax and AUC0-24 (Yew, 2001). High peak plasma concentration of aminoglycosides is 
associated with increased rate of survival and better therapeutic response in patients. 
However, due to the narrow therapeutic index of aminoglycosides and the fact that the 
concentration required for therapeutic effects is close to the concentration that potentially 
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causes toxic effects, care must be taken when administering kanamycin in patients with renal 
impairment.  
 
Most of our patients had a low peak plasma concentration of kanamycin when compared to 
the literature (Cronk and Naumann, 1959; Cabana and Taggart, 1973; Clarke et al., 1974; 
Doluiso et al., 1973). The low Cmax could result in poor response to therapy and increased 
risk of selection of drug-resistant organisms. It has been suggested that clinicians should aim 
for a Cmax of 20–35 µg/ml and a Ctrough (trough level) of <10 µg/ml when kanamycin is given 
intramuscularly (Peloquin, 2002).  Based on our results, the median Ctrough of kanamycin in 
HIV -positive and in HIV -negative patients was 7.8 (0.66-9.98) µg/ml and 8.6 (0.77-11.76) 
µg/ml respectively. This further explains that kanamycin plasma levels were not toxic in our 
patients. 
 
Furthermore, AUC is associated with bioavailability and clearance. Increased total clearance 
results in a fall in the AUC over 24 hours, and vice versa. Also, bioavailability is an 
important factor that determines clinical efficacy and the therapeutic response of a drug 
(Burgess, 1999). It was observed in most patients that increased clearance of kanamycin 
resulted in a fall in the AUC0-24. This means that there was a reduction in the rate and extent 
of absorption of kanamycin, which could potentially result in the development of drug 
resistance. 
 
5.16 Limitations of the study 
We had an unequal distribution of patients in the HIV-positive and HIV-negative groups. 
Twenty-five patients volunteered to participate in the study, of whom 11 were HIV-positive. 
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Also, there were very few patients with kidney dysfunction and no drug–drug interaction was 
observed between kanamycin and co-administered medications. 
 
There was no balance in the CD4 count and viral load in HIV-positive patients. Five patients 
had a CD4 count of <100 cells/mm
3
 and six had a CD4 count of >100 cells/mm
3
. Some 
patients were in the early stage of the disease, while some had advanced HIV infection; thus, 
it might be difficult to conclude if HIV infection was responsible for the abnormal PK 
parameters seen in these patients. In addition, studies on the PK of kanamycin are very 
scarce, especially in sub-Saharan Africa. Thus, comparison of our results with previously 
published studies for similarities or differences in the PK parameters was limited. 
Furthermore, the cost of getting more volunteers to participate in the study would have been 
very expensive. This impeded the assessment of whether HIV infection, kidney dysfunction 
or drug interaction influences the PK of kanamycin. 
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
 
6.1 Conclusion 
The aim of the study was to determine kanamycin plasma concentrations using LC-MS and to 
describe the PK of kanamycin in patients with MDR-TB infection and in patients with MDR-
TB co-infected with HIV during their course of treatment. In addition, we also examined 
whether HIV, kidney dysfunction and drug interactions influenced the PK of kanamycin.  
 
Based on the results obtained, we can conclude that objectives of the present study were 
achieved: 
 The LC-MS analysis method is highly specific, highly sensitive and reproducible in the 
detection and quantification of the plasma concentrations of kanamycin.  
 The PK of kanamycin in patients with MDR-TB and in those with MDR-TB co-infected with 
HIV was described. 
 HIV infection does not have any influence on the PK of kanamycin. 
 Changes in renal function do not influence the PK of kanamycin.  
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6.2 Recommendations  
Based on the above mentioned limitations, the following should be considered for future 
studies: 
 
 PK/PD relationship of kanamycin should be determined, because it quantifies the activity of 
an antibiotic and describes the time course of action of the antibiotic. 
 
 Kanamycin-free plasma concentration should be evaluated, because the free plasma 
concentration is responsible for therapeutic effects. 
 
 The minimum inhibitory concentration (MIC) of kanamycin should be determined on each 
patient’s sputum. MIC is a good predictor of the potency of anti-bacteria activity. 
 
 
  Sputum conversion for each patient should be recorded five times during the treatment. This 
indicates if MDR-TB therapy was successful. 
 
 Other MDR-TB treatment outcomes (cure, treatment failure, death and defaultment) should 
be determined. 
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